{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:46:47Z","timestamp":1785026807482,"version":"3.55.0"},"reference-count":245,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003693","name":"Korea Institute of Science and Technology","doi-asserted-by":"publisher","award":["2E33791"],"award-info":[{"award-number":["2E33791"]}],"id":[{"id":"10.13039\/501100003693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003693","name":"Korea Institute of Science and Technology","doi-asserted-by":"publisher","award":["2V10650"],"award-info":[{"award-number":["2V10650"]}],"id":[{"id":"10.13039\/501100003693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"national research foundation of korea","doi-asserted-by":"crossref","award":["NRF-2022R1C1C1006143"],"award-info":[{"award-number":["NRF-2022R1C1C1006143"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12272-025-01582-w","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T15:59:24Z","timestamp":1763395164000},"page":"1253-1298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Boron-containing anticancer agents: a target-centric review of structure\u2013activity relationships and clinical pipeline"],"prefix":"10.1007","volume":"48","author":[{"given":"Haeun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4189-6774","authenticated-orcid":false,"given":"Byungsun","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"issue":"1","key":"1582_CR1","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1124\/mol.105.021311","volume":"70","author":"G Achanta","year":"2006","unstructured":"Achanta G, Modzelewska A, Feng L, Khan SR, Huang P (2006) A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome. Mol Pharmacol 70(1):426\u2013433. https:\/\/doi.org\/10.1124\/mol.105.021311","journal-title":"Mol Pharmacol"},{"issue":"11","key":"1582_CR2","doi-asserted-by":"publisher","first-page":"5224","DOI":"10.1021\/cr500642d","volume":"115","author":"A Adamczyk-Wo\u017aniak","year":"2015","unstructured":"Adamczyk-Wo\u017aniak A, Borys KM, Sporzy\u0144ski A (2015) Recent developments in the chemistry and biological applications of benzoxaboroles. Chem Rev 115(11):5224\u20135247. https:\/\/doi.org\/10.1021\/cr500642d","journal-title":"Chem Rev"},{"issue":"8","key":"1582_CR3","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1021\/cr000230w","volume":"101","author":"JA Adams","year":"2001","unstructured":"Adams JA (2001) Kinetic and catalytic mechanisms of protein kinases. Chem Rev 101(8):2271\u20132290. https:\/\/doi.org\/10.1021\/cr000230w","journal-title":"Chem Rev"},{"key":"1582_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/s0305-7372(03)00081-1","volume":"29","author":"J Adams","year":"2003","unstructured":"Adams J (2003) The proteasome: structure, function, and role in the cell. Cancer Treat Rev 29:3\u20139. https:\/\/doi.org\/10.1016\/s0305-7372(03)00081-1","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"1582_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1023\/a:1006321828515","volume":"18","author":"J Adams","year":"2000","unstructured":"Adams J, Palombella VJ, Elliott PJ (2000) Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 18(2):109\u2013121. https:\/\/doi.org\/10.1023\/a:1006321828515","journal-title":"Invest New Drugs"},{"key":"1582_CR6","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.1038\/s41598-024-55604-6","volume":"14","author":"GY Ahmed","year":"2024","unstructured":"Ahmed GY, Osman AA, Mukhtar A (2024) Acetylcholinesterase enzyme among cancer patients a potential diagnostic and prognostic indicator a multicenter case-control study. Sci Rep 14:5127. https:\/\/doi.org\/10.1038\/s41598-024-55604-6","journal-title":"Sci Rep"},{"issue":"16","key":"1582_CR7","doi-asserted-by":"publisher","first-page":"7257","DOI":"10.1073\/pnas.1001529107","volume":"107","author":"HMHG Albers","year":"2010","unstructured":"Albers HMHG, Dong A, van Meeteren LA, Egan DA, Sunkara M, van Tilburg EW, Schuurman K, van Tellingen O, Morris AJ, Smyth SS, Moolenaar WH, Ovaa H (2010) Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci USA 107(16):7257\u20137262. https:\/\/doi.org\/10.1073\/pnas.1001529107","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1582_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2023.2220084","volume":"38","author":"MK Al-Omari","year":"2023","unstructured":"Al-Omari MK, Elaarag M, Al-Zoubi RM, AlQudimat AR, Zarour AA, Al-Hurani EA, Fares ZE, Alkharraz LM, Shkoor M, Bani-Yaseen AD, Aboumarzouk OM, Yassin A, Al-Ansari AA (2023) Organoboronic acids\/esters as effective drug and prodrug candidates in cancer treatments: challenge and hope. J Enz Inhib Med Chem 38(1):2220084. https:\/\/doi.org\/10.1080\/14756366.2023.2220084","journal-title":"J Enz Inhib Med Chem"},{"issue":"80","key":"1582_CR9","doi-asserted-by":"publisher","first-page":"11983","DOI":"10.1039\/c6cc06399c","volume":"52","author":"V Alterio","year":"2016","unstructured":"Alterio V, Cadoni R, Esposito D, Vullo D, Fiore AD, Monti SM, Caporale A, Ruvo M, Sechi M, Dumy P, Supuran CT, Simone GD, Winum JY (2016) Benzoxaborole as a new chemotype for carbonic anhydrase inhibition. Chem Commun 52(80):11983\u201311986. https:\/\/doi.org\/10.1039\/c6cc06399c","journal-title":"Chem Commun"},{"issue":"9","key":"1582_CR10","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.3390\/catal10091008","volume":"10","author":"A Angeli","year":"2020","unstructured":"Angeli A, Carta F, Supuran CT (2020) Carbonic anhydrases: versatile and useful biocatalysts in chemistry and biochemistry. Catalysts 10(9):1008. https:\/\/doi.org\/10.3390\/catal10091008","journal-title":"Catalysts"},{"key":"1582_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1021\/acs.accounts.4c00691","volume":"58","author":"J Ant\u00f3nio","year":"2025","unstructured":"Ant\u00f3nio J, Roque IL, Santos FMF, Gois PMP (2025) Designing functional and responsive molecules with boronic acids. Acc Chem Res 58:673\u2013687. https:\/\/doi.org\/10.1021\/acs.accounts.4c00691","journal-title":"Acc Chem Res"},{"issue":"5","key":"1582_CR12","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","volume":"112","author":"AA Argyriou","year":"2008","unstructured":"Argyriou AA, Iconomou G, Kalofonos HP (2008) Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 112(5):1593\u20131599. https:\/\/doi.org\/10.1182\/blood-2008-04-149385","journal-title":"Blood"},{"issue":"3","key":"1582_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2174\/156802606776173474","volume":"6","author":"EA Ariazi","year":"2006","unstructured":"Ariazi EA, Ariazi JL, Cordera F, Jordan VC (2006) Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 6(3):195\u2013213. https:\/\/doi.org\/10.2174\/156802606776173474","journal-title":"Curr Top Med Chem"},{"key":"1582_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j\/bioorg.2023.106427","volume":"133","author":"H Atta","year":"2023","unstructured":"Atta H, Alzahaby N, Hamdy NM, Emam SH, Sonousi A (2023) New trends in synthetic drugs and natural products targeting 20S proteasomes in cancers. Bioorg Chem 133:106427. https:\/\/doi.org\/10.1016\/j\/bioorg.2023.106427","journal-title":"Bioorg Chem"},{"issue":"7","key":"1582_CR15","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.biocel.2013.03.004","volume":"45","author":"CJD Austin","year":"2013","unstructured":"Austin CJD, Kahlert J, Kassiou M, Rendina LM (2013) The translocator protein (TSPO): a novel target for cancer chemotherapy. Int J Biochem Cell Biol 45(7):1212\u20131216. https:\/\/doi.org\/10.1016\/j.biocel.2013.03.004","journal-title":"Int J Biochem Cell Biol"},{"issue":"21","key":"1582_CR16","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1039\/b909504g","volume":"7","author":"HS Ban","year":"2009","unstructured":"Ban HS, Usui T, Nabeyama W, Morita H, Fukuzawa K, Nakamura H (2009) Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase. Org Biomol Chem 7(21):4415. https:\/\/doi.org\/10.1039\/b909504g","journal-title":"Org Biomol Chem"},{"key":"1582_CR17","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/cac2.12582","volume":"44","author":"RF Barth","year":"2024","unstructured":"Barth RF, Gupta N, Kawabata S (2024) Evaluation of sodium borocaptate (BSH) and boronophenylalanine (BPA) as boron delivery agents for neutron capture therapy (NCT) of cancer: an update and a guide for the future clinical evaluation of new boron delivery agents for NCT. Cancer Commun 44:893\u2013909. https:\/\/doi.org\/10.1002\/cac2.12582","journal-title":"Cancer Commun"},{"issue":"2","key":"1582_CR18","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1210\/endo.142.2.7932","volume":"142","author":"DJ Bentrem","year":"2001","unstructured":"Bentrem DJ, Dardes RC, Liu H, MacGregor-Schafer J, Zapf JW, Jordan VC (2001) Molecular mechanism of action at estrogen receptor \u03b1 of a new clinically relevant antiestrogen (GW7604) related to tamoxifen. Endocrinology 142(2):838\u2013846. https:\/\/doi.org\/10.1210\/endo.142.2.7932","journal-title":"Endocrinology"},{"issue":"8","key":"1582_CR19","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/cam4.2278","volume":"8","author":"R Bishnoi","year":"2019","unstructured":"Bishnoi R, Hong YR, Shah C, Ali A, Skelton WP, Huo J, Dang NH, Dang LH (2019) Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: a surveillance epidemiology and endpoint research medicare study. Cancer Med 8(8):3918\u20133927. https:\/\/doi.org\/10.1002\/cam4.2278","journal-title":"Cancer Med"},{"issue":"4","key":"1582_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nchembio866","volume":"3","author":"JA Blair","year":"2007","unstructured":"Blair JA, Rauh D, Kung C, Yun CH, Fan QW, Rode H, Zhang C, Eck MJ, Weiss WA, Shokat KM (2007) Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol 3(4):229\u2013238. https:\/\/doi.org\/10.1038\/nchembio866","journal-title":"Nat Chem Biol"},{"issue":"14","key":"1582_CR21","doi-asserted-by":"publisher","first-page":"9759","DOI":"10.1021\/acs.jmedchem.1c00624","volume":"64","author":"G Bononi","year":"2021","unstructured":"Bononi G, Tuccinardi T, Rizzolio F, Granchi C (2021) \u0391\/\u03b2-hydrolase domain (ABHD) inhibitors as new potential therapeutic options against lipid-related diseases. J Med Chem 64(14):9759\u20139785. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00624","journal-title":"J Med Chem"},{"issue":"5630","key":"1582_CR22","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/269702a0","volume":"269","author":"C Braestrup","year":"1977","unstructured":"Braestrup C, Albrechtsen R, Squires RF (1977) High densities of benzodiazepine receptors in human cortical areas. Nature 269(5630):702\u2013704. https:\/\/doi.org\/10.1038\/269702a0","journal-title":"Nature"},{"issue":"13","key":"1582_CR23","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.2174\/15680266106061345","volume":"6","author":"J Busch-Petersen","year":"2006","unstructured":"Busch-Petersen J (2006) Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases. Curr Top Med Chem 6(13):1345\u20131352. https:\/\/doi.org\/10.2174\/15680266106061345","journal-title":"Curr Top Med Chem"},{"issue":"12","key":"1582_CR24","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1021\/bc100195s","volume":"21","author":"A Cappelli","year":"2010","unstructured":"Cappelli A, Valenti S, Mancini A, Giuliani G, Anzini M, Altieri S, Bortolussi S, Ferrari C, Clerici AM, Zonta C, Carraro F, Filippi I, Giorgi G, Donati A, Ristori S, Vomero S, Concas A, Biggio G (2010) Carborane-conjugated 2-quinolinecarboxamide ligands of the translocator protein for boron neutron capture therapy. Bioconjug Chem 21(12):2213\u20132221. https:\/\/doi.org\/10.1021\/bc100195s","journal-title":"Bioconjug Chem"},{"issue":"4","key":"1582_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2020.151075","volume":"99","author":"V \u010cerm\u00e1k","year":"2020","unstructured":"\u010cerm\u00e1k V, Dost\u00e1l V, Jel\u00ednek M, Libusov\u00e1 L, Kov\u00e1\u0159 J, R\u00f6sel D, Br\u00e1bek J (2020) Microtubule-targeting agents and their impact on cancer treatment. Eur J Cell Biol 99(4):151075. https:\/\/doi.org\/10.1016\/j.ejcb.2020.151075","journal-title":"Eur J Cell Biol"},{"issue":"16","key":"1582_CR26","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1158\/1078-0432.ccr-11-0476","volume":"17","author":"D Chauhan","year":"2011","unstructured":"Chauhan D, Zhou ZT, Kuhn D, Orlowski R, Raje N, Richardson P, Anderson KC (2011) In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 17(16):5311\u20135321. https:\/\/doi.org\/10.1158\/1078-0432.ccr-11-0476","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1582_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031242","volume":"23","author":"A Chimento","year":"2022","unstructured":"Chimento A, De Luca A, Avena P, De Amicis F, Casaburi I, Sirianni R, Pezzi V (2022) Estrogen receptors-mediated apoptosis in hormone-dependent cancers. Int J Mol Sci 23(3):1242. https:\/\/doi.org\/10.3390\/ijms23031242","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1582_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1089\/ars.2014.5863","volume":"23","author":"AC Chueh","year":"2015","unstructured":"Chueh AC, Tse JWT, T\u00f6gel L, Mariadason JM (2015) Mechanisms of histone deacetylase inhibitor-regulated gene expression in cancer cells. Antioxid Redox Signal 23(1):66\u201384. https:\/\/doi.org\/10.1089\/ars.2014.5863","journal-title":"Antioxid Redox Signal"},{"issue":"24","key":"1582_CR29","doi-asserted-by":"publisher","first-page":"7151","DOI":"10.1093\/emboj\/17.24.7151","volume":"17","author":"A Ciechanover","year":"1998","unstructured":"Ciechanover A (1998) The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 17(24):7151\u20137160. https:\/\/doi.org\/10.1093\/emboj\/17.24.7151","journal-title":"EMBO J"},{"issue":"7","key":"1582_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076834","volume":"24","author":"L Clusan","year":"2023","unstructured":"Clusan L, Ferri\u00e8re F, Flouriot G, Pakdel F (2023) A basic review on estrogen receptor signaling pathways in breast cancer. Int J Mol Sci 24(7):6834. https:\/\/doi.org\/10.3390\/ijms24076834","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1582_CR31","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1158\/1535-7163.mct-05-0147","volume":"5","author":"J Codony-Servat","year":"2006","unstructured":"Codony-Servat J, Tapia MA, Bosch M, Oliva C, Domingo-Domenech J, Mellado B, Rolfe M, Ross JS, Gascon P, Rovira A, Albanell J (2006) Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 5(3):665\u2013675. https:\/\/doi.org\/10.1158\/1535-7163.mct-05-0147","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"1582_CR32","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nrd773","volume":"1","author":"P Cohen","year":"2002","unstructured":"Cohen P (2002) Protein kinases \u2014 the major drug targets of the twenty-first century? Nat Rev Drug Discov 1(4):309\u2013315. https:\/\/doi.org\/10.1038\/nrd773","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"1582_CR33","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1210\/endo-128-6-2867","volume":"128","author":"PS Cooke","year":"1991","unstructured":"Cooke PS, Young P, Cunha GR (1991) Androgen receptor expression in developing male reproductive organs. Endocrinology 128(6):2867\u20132873. https:\/\/doi.org\/10.1210\/endo-128-6-2867","journal-title":"Endocrinology"},{"issue":"13","key":"1582_CR34","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1002\/chem.201705181","volume":"24","author":"M Couto","year":"2018","unstructured":"Couto M, Garc\u00eda MF, Alam\u00f3n C, Cabrera M, Cabral P, Merlino A, Teixidor F, Cerecetto H, Vi\u00f1as C (2018) Discovery of potent EGFR inhibitors through the incorporation of a 3D-aromatic-boron-rich-cluster into the 4-anilinoquinazoline scaffold: potential drugs for glioma treatment. Chemistry 24(13):3122\u20133126. https:\/\/doi.org\/10.1002\/chem.201705181","journal-title":"Chemistry"},{"issue":"9","key":"1582_CR35","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1517\/13543784.16.9.1459","volume":"16","author":"CC Cunningham","year":"2007","unstructured":"Cunningham CC (2007) Talabostat. Expert Opin Investig Drugs 16(9):1459\u20131465. https:\/\/doi.org\/10.1517\/13543784.16.9.1459","journal-title":"Expert Opin Investig Drugs"},{"key":"1582_CR36","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1038\/s41467-019-10979-3","volume":"10","author":"M Czystowska-Kuzmicz","year":"2019","unstructured":"Czystowska-Kuzmicz M, Sosnowska A, Nowis D, Ramji K, Szajnik M, Chlebowska-Tuz J, Wolinska E, Gaj P, Grazul M, Pilch Z, Zerrouqi A, Graczyk-Jarzynka A, Soroczynska K, Cierniak S, Koktysz R, Elishaev E, Gruca S, Stefanowicz A, Blaszczyk R, Borek B, Gzik A, Whiteside T, Golab J (2019) Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nat Commun 10:3000. https:\/\/doi.org\/10.1038\/s41467-019-10979-3","journal-title":"Nat Commun"},{"key":"1582_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2022.116748","volume":"63","author":"BC Das","year":"2022","unstructured":"Das BC, Shareef MA, Das S, Nandwana NK, Das Y, Saito M, Weiss LM (2022) Boron-containing heterocycles as promising pharmacological agents. Bioorg Med Chem 63:116748. https:\/\/doi.org\/10.1016\/j.bmc.2022.116748","journal-title":"Bioorg Med Chem"},{"issue":"6","key":"1582_CR38","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nchembio.362","volume":"6","author":"FJ Dekker","year":"2010","unstructured":"Dekker FJ, Rocks O, Vartak N, Menninger S, Hedberg C, Balamurugan R, Wetzel S, Renner S, Gerauer M, Sch\u00f6lermann B, Rusch M, Kramer JW, Rauh D, Coates GW, Brunsveld L, Bastiaens PIH, Waldmann H (2010) Small-molecule inhibition of APT1 affects Ras localization and signaling. Nat Chem Biol 6(6):449\u2013456. https:\/\/doi.org\/10.1038\/nchembio.362","journal-title":"Nat Chem Biol"},{"issue":"1","key":"1582_CR39","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/(sici)1098-2388(200001\/02)18:1<52::aid-ssu8>3.0.co;2-6","volume":"18","author":"LJ Denis","year":"2000","unstructured":"Denis LJ, Griffiths K (2000) Endocrine treatment in prostate cancer. Semin Surg Oncol 18(1):52\u201374. https:\/\/doi.org\/10.1002\/(sici)1098-2388(200001\/02)18:1%3c52::aid-ssu8%3e3.0.co;2-6","journal-title":"Semin Surg Oncol"},{"issue":"11","key":"1582_CR40","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40265-014-0251-3","volume":"74","author":"S Dhillon","year":"2014","unstructured":"Dhillon S, Clark M (2014) Ceritinib: first global approval. Drugs 74(11):1285\u20131291. https:\/\/doi.org\/10.1007\/s40265-014-0251-3","journal-title":"Drugs"},{"issue":"3","key":"1582_CR41","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1023\/a:1006348907994","volume":"17","author":"K Dhingra","year":"1999","unstructured":"Dhingra K (1999) Antiestrogens \u2013 tamoxifen, SERMs and beyond. Invest New Drugs 17(3):285\u2013311. https:\/\/doi.org\/10.1023\/a:1006348907994","journal-title":"Invest New Drugs"},{"issue":"21","key":"1582_CR42","doi-asserted-by":"publisher","first-page":"5441","DOI":"10.1158\/0008-5472.can-12-1600","volume":"72","author":"F Di Virgilio","year":"2012","unstructured":"Di Virgilio F (2012) Purines, purinergic receptors, and cancer. Cancer Res 72(21):5441\u20135447. https:\/\/doi.org\/10.1158\/0008-5472.can-12-1600","journal-title":"Cancer Res"},{"issue":"5\u20136","key":"1582_CR43","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.drudis.2010.01.008","volume":"15","author":"LR Dick","year":"2010","unstructured":"Dick LR, Fleming PE (2010) Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 15(5\u20136):243\u2013249. https:\/\/doi.org\/10.1016\/j.drudis.2010.01.008","journal-title":"Drug Discov Today"},{"issue":"4","key":"1582_CR44","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1021\/jm7010589","volume":"51","author":"BD Dorsey","year":"2008","unstructured":"Dorsey BD, Iqbal M, Chatterjee S, Menta E, Bernardini R, Bernareggi A, Cassar\u00e0 PG, D\u2019Arasmo G, Ferretti E, De Munari S, Oliva A, Pezzoni G, Allievi C, Strepponi I, Ruggeri B, Ator MA, Williams M, Mallamo JP (2008) Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem 51(4):1068\u20131072. https:\/\/doi.org\/10.1021\/jm7010589","journal-title":"J Med Chem"},{"key":"1582_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112460","volume":"200","author":"J Dvo\u0159anov\u00e1","year":"2020","unstructured":"Dvo\u0159anov\u00e1 J, Kugler M, Holub J, \u0160\u00edcha V, Das V, Nekvinda J, El Anwar S, Havr\u00e1nek M, Posp\u00ed\u0161ilov\u00e1 K, F\u00e1bry M, Kr\u00e1l V, Medved\u00edkov\u00e1 M, Mat\u011bjkov\u00e1 S, Li\u0161kov\u00e1 B, Gursk\u00e1 S, D\u017eub\u00e1k P, Brynda J, Hajd\u00fach M, Gr\u00fcner B, \u0158ez\u00e1\u010dov\u00e1 P (2020) Sulfonamido carboranes as highly selective inhibitors of cancer-specific carbonic anhydrase IX. Eur J Med Chem 200:112460. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112460","journal-title":"Eur J Med Chem"},{"issue":"6","key":"1582_CR46","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.clon.2009.04.007","volume":"21","author":"RM Eager","year":"2009","unstructured":"Eager RM, Cunningham CC, Senzer N, Richards DA, Raju RN, Jones B, Uprichard M, Nemunaitis J (2009) Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer. Clin Oncol (r Coll Radiol) 21(6):464\u2013472. https:\/\/doi.org\/10.1016\/j.clon.2009.04.007","journal-title":"Clin Oncol (r Coll Radiol)"},{"issue":"8","key":"1582_CR47","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1021\/ja210719s","volume":"134","author":"GA Ellis","year":"2012","unstructured":"Ellis GA, Palte MJ, Raines RT (2012) Boronate-mediated biologic delivery. J Am Chem Soc 134(8):3631\u20133634. https:\/\/doi.org\/10.1021\/ja210719s","journal-title":"J Am Chem Soc"},{"issue":"17","key":"1582_CR48","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1016\/s0960-894x(99)00436-9","volume":"9","author":"Y Endo","year":"1999","unstructured":"Endo Y, Yoshimi T, Kimura K, Itai A (1999) Protein kinase C modulators bearing dicarba-closo-dodecaborane as a hydrophobic pharmacophore. Bioorg Med Chem Lett 9(17):2561\u20132564. https:\/\/doi.org\/10.1016\/s0960-894x(99)00436-9","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"1582_CR49","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/s1074-5521(01)00016-3","volume":"8","author":"Y Endo","year":"2001","unstructured":"Endo Y, Iijima T, Yamakoshi Y, Fukasawa H, Miyaura C, Inada M, Kubo A, Itai A (2001) Potent estrogen agonists based on carborane as a hydrophobic skeletal structure. Chem Biol 8(4):341\u2013355. https:\/\/doi.org\/10.1016\/s1074-5521(01)00016-3","journal-title":"Chem Biol"},{"issue":"9","key":"1582_CR50","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1351\/pac200375091197","volume":"75","author":"Y Endo","year":"2003","unstructured":"Endo Y, Yoshimi T, Miyaura C (2003) Boron clusters for medicinal drug design: selective estrogen receptor modulators bearing carborane. Pure Appl Chem 75(9):1197\u20131205. https:\/\/doi.org\/10.1351\/pac200375091197","journal-title":"Pure Appl Chem"},{"issue":"13","key":"1582_CR51","doi-asserted-by":"publisher","first-page":"4990","DOI":"10.18632\/oncotarget.2071","volume":"5","author":"SA Ezell","year":"2014","unstructured":"Ezell SA, Mayo M, Bihani T, Tepsuporn S, Wang S, Passino M, Grosskurth SE, Collins M, Parmentier J, Reimer C, Byth KF (2014) Synergistic induction of apoptosis by combination of BTK and dual mTORC1\/2 inhibitors in diffuse large B cell lymphoma. Oncotarget 5(13):4990\u20135001. https:\/\/doi.org\/10.18632\/oncotarget.2071","journal-title":"Oncotarget"},{"issue":"23","key":"1582_CR52","doi-asserted-by":"publisher","first-page":"7261","DOI":"10.1073\/pnas.1502670112","volume":"112","author":"J Fan","year":"2015","unstructured":"Fan J, Campioli E, Midzak A, Culty M, Papadopoulos V (2015) Conditional steroidogenic cell-targeted deletion of TSPO unveils a crucial role in viability and hormone-dependent steroid formation. Proc Natl Acad Sci USA 112(23):7261\u20137266. https:\/\/doi.org\/10.1073\/pnas.1502670112","journal-title":"Proc Natl Acad Sci USA"},{"key":"1582_CR53","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.ejmech.2019.06.092","volume":"179","author":"GFS Fernandes","year":"2019","unstructured":"Fernandes GFS, Denny WA, Dos Santos JL (2019) Boron in drug design: recent advances in the development of new therapeutic agents. Eur J Med Chem 179:791\u2013804. https:\/\/doi.org\/10.1016\/j.ejmech.2019.06.092","journal-title":"Eur J Med Chem"},{"key":"1582_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.673647","volume":"9","author":"CW Fhu","year":"2021","unstructured":"Fhu CW, Ali A (2021) Protein lipidation by palmitoylation and myristoylation in cancer. Front Cell Dev Biol 9:673647. https:\/\/doi.org\/10.3389\/fcell.2021.673647","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"1582_CR55","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1073\/pnas.88.4.1556","volume":"88","author":"GR Flentke","year":"1991","unstructured":"Flentke GR, Munoz E, Huber BT, Plaut AG, Kettner CA, Bachovchin WW (1991) Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. Proc Natl Acad Sci U S A 88(4):1556\u20131559. https:\/\/doi.org\/10.1073\/pnas.88.4.1556","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"1582_CR56","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1182\/blood-2004-04-1493","volume":"104","author":"K Fotoohi","year":"2004","unstructured":"Fotoohi K (2004) Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: implications for efficacy of methotrexate therapy. Blood 104(13):4194\u20134201. https:\/\/doi.org\/10.1182\/blood-2004-04-1493","journal-title":"Blood"},{"key":"1582_CR57","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1126\/science.8066447","volume":"265","author":"DW Fry","year":"1994","unstructured":"Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW, Bridges AJ (1994) A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265:1093\u20131095. https:\/\/doi.org\/10.1126\/science.8066447","journal-title":"Science"},{"issue":"14","key":"1582_CR58","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1021\/jm050115j","volume":"48","author":"S Fujii","year":"2005","unstructured":"Fujii S, Goto T, Ohta K, Hashimoto Y, Suzuki T, Ohta S, Endo Y (2005a) Potent androgen antagonists based on carborane as a hydrophobic core structure. J Med Chem 48(14):4654\u20134662. https:\/\/doi.org\/10.1021\/jm050115j","journal-title":"J Med Chem"},{"issue":"1","key":"1582_CR59","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.bmcl.2004.09.091","volume":"15","author":"S Fujii","year":"2005","unstructured":"Fujii S, Hashimoto Y, Suzuki T, Ohta S, Endo Y (2005b) A new class of androgen receptor antagonists bearing carborane in place of a steroidal skeleton. Bioorg Med Chem Lett 15(1):227\u2013230. https:\/\/doi.org\/10.1016\/j.bmcl.2004.09.091","journal-title":"Bioorg Med Chem Lett"},{"key":"1582_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2022.106189","volume":"145","author":"M Gasparrini","year":"2022","unstructured":"Gasparrini M, Audrito V (2022) NAMPT: a critical driver and therapeutic target for cancer. Int J Biochem Cell Biol 145:106189. https:\/\/doi.org\/10.1016\/j.biocel.2022.106189","journal-title":"Int J Biochem Cell Biol"},{"key":"1582_CR62","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejmech.2017.01.034","volume":"128","author":"Y Ge","year":"2017","unstructured":"Ge Y, Li A, Wu J, Feng H, Wang L, Liu H, Xu Y, Xu Q, Zhao L, Li Y (2017) Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors. Eur J Med Chem 128:180\u2013191. https:\/\/doi.org\/10.1016\/j.ejmech.2017.01.034","journal-title":"Eur J Med Chem"},{"key":"1582_CR63","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/j.ejmech.2017.10.080","volume":"143","author":"Y Ge","year":"2018","unstructured":"Ge Y, Wang C, Song S, Huang J, Liu Z, Li Y, Meng Q, Zhang J, Yao J, Liu K, Ma X, Sun X (2018) Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma. Eur J Med Chem 143:1847\u20131857. https:\/\/doi.org\/10.1016\/j.ejmech.2017.10.080","journal-title":"Eur J Med Chem"},{"key":"1582_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106976","volume":"143","author":"S Giovannuzzi","year":"2024","unstructured":"Giovannuzzi S, Nikitjuka A, Resende BRP, Smietana M, Nocentini A, Supuran CT, Winum JY (2024a) Boron-containing carbonic anhydrases inhibitors. Bioorg Chem 143:106976. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106976","journal-title":"Bioorg Chem"},{"key":"1582_CR65","doi-asserted-by":"publisher","first-page":"18221","DOI":"10.1021\/acs.jmedchem.4c01516","volume":"67","author":"S Giovannuzzi","year":"2024","unstructured":"Giovannuzzi S, Nikitjuka A, Angeli A, Smietana M, Massardi ML, Turati M, Ronca R, Bonardi A, Nocentini A, Ferraroni M, Supuran CT, Winum JY (2024b) Benzoxaborinine, new chemotype for carbonic anhydrase inhibition: ex novo synthesis, crystallography, in silico studies, and anti-melanoma cell line activity. J Med Chem 67:18221\u201318234. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01516","journal-title":"J Med Chem"},{"issue":"23","key":"1582_CR66","doi-asserted-by":"publisher","first-page":"6414","DOI":"10.1016\/j.bmc.2005.06.061","volume":"13","author":"T Goto","year":"2005","unstructured":"Goto T, Ohta K, Suzuki T, Ohta S, Endo Y (2005) Design and synthesis of novel androgen receptor antagonists with sterically bulky icosahedral carboranes. Bioorg Med Chem 13(23):6414\u20136424. https:\/\/doi.org\/10.1016\/j.bmc.2005.06.061","journal-title":"Bioorg Med Chem"},{"issue":"13","key":"1582_CR67","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.1021\/jm100316f","volume":"53","author":"T Goto","year":"2010","unstructured":"Goto T, Ohta K, Fujii S, Ohta S, Endo Y (2010) Design and synthesis of androgen receptor full antagonists bearing a p-carborane cage: promising ligands for anti-androgen withdrawal syndrome. J Med Chem 53(13):4917\u20134926. https:\/\/doi.org\/10.1021\/jm100316f","journal-title":"J Med Chem"},{"key":"1582_CR68","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1021\/acs.chemrev.3c00663","volume":"124","author":"RJ Grams","year":"2024","unstructured":"Grams RJ, Santos WL, Scorei IR, Abad-Garc\u00eda A, Rosenblum CA, Bita A, Cerecetto H, Vi\u00f1as C, Soriano-Urs\u00faa MA (2024) The rise of boron-containing compounds: advancements in synthesis, medicinal chemistry, and emerging pharmacology. Chem Rev 124:2441\u20132511. https:\/\/doi.org\/10.1021\/acs.chemrev.3c00663","journal-title":"Chem Rev"},{"issue":"4","key":"1582_CR69","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1158\/1535-7163.mct-10-0615","volume":"10","author":"E Grande","year":"2011","unstructured":"Grande E, Bol\u00f3s MV, Arriola E (2011) Targeting oncogenic ALK: a promising strategy for cancer treatment. Mol Cancer Ther 10(4):569\u2013579. https:\/\/doi.org\/10.1158\/1535-7163.mct-10-0615","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"1582_CR70","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.str.2005.11.019","volume":"14","author":"M Groll","year":"2006","unstructured":"Groll M, Berkers CR, Ploegh HL, Ovaa H (2006) Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 14(3):451\u2013456. https:\/\/doi.org\/10.1016\/j.str.2005.11.019","journal-title":"Structure"},{"issue":"5","key":"1582_CR71","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1172\/jci76094","volume":"125","author":"S Gross","year":"2015","unstructured":"Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP (2015) Targeting cancer with kinase inhibitors. J Clin Invest 125(5):1780\u20131789. https:\/\/doi.org\/10.1172\/jci76094","journal-title":"J Clin Invest"},{"key":"1582_CR72","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1021\/acsptsci.5c00238","volume":"8","author":"YM Guo","year":"2025","unstructured":"Guo YM, Cui Y, Wang XQ (2025) Recent development of boron-containing small-molecule anticancer agents. ACS Pharmacol Transl Sci 8:2384\u20132400. https:\/\/doi.org\/10.1021\/acsptsci.5c00238","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"15","key":"1582_CR73","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1016\/j.bmc.2017.05.049","volume":"25","author":"L Han","year":"2017","unstructured":"Han L, Wen Y, Li R, Xu B, Ge Z, Wang X, Cheng T, Cui J, Li R (2017a) Synthesis and biological activity of peptide proline-boronic acids as proteasome inhibitors. Bioorg Med Chem 25(15):4031\u20134044. https:\/\/doi.org\/10.1016\/j.bmc.2017.05.049","journal-title":"Bioorg Med Chem"},{"key":"1582_CR74","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ejmech.2016.10.023","volume":"125","author":"LQ Han","year":"2017","unstructured":"Han LQ, Yuan X, Wu XY, Li RD, Xu B, Cheng Q, Liu ZM, Zhou TY, An HY, Wang X, Cheng TM, Ge ZM, Cui JR, Li RT (2017b) Urea-containing peptide boronic acids as potent proteasome inhibitors. Eur J Med Chem 125:925\u2013939. https:\/\/doi.org\/10.1016\/j.ejmech.2016.10.023","journal-title":"Eur J Med Chem"},{"issue":"21","key":"1582_CR75","first-page":"7436","volume":"63","author":"M Hasmann","year":"2003","unstructured":"Hasmann M, Schemainda I (2003) FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 63(21):7436\u20137442","journal-title":"Cancer Res"},{"issue":"11","key":"1582_CR76","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1007\/s00018-008-7452-4","volume":"65","author":"H Hatcher","year":"2008","unstructured":"Hatcher H, Planalp R, Cho J, Torti FM, Torti SV (2008) Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 65(11):1631\u20131652. https:\/\/doi.org\/10.1007\/s00018-008-7452-4","journal-title":"Cell Mol Life Sci"},{"issue":"7","key":"1582_CR77","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/anie.199309501","volume":"32","author":"MF Hawthorne","year":"1993","unstructured":"Hawthorne MF (1993) The role of chemistry in the development of boron neutron capture therapy of cancer. Angew Chem Int Ed 32(7):950\u2013984. https:\/\/doi.org\/10.1002\/anie.199309501","journal-title":"Angew Chem Int Ed"},{"issue":"2","key":"1582_CR78","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1210\/er.2002-0032","volume":"25","author":"CA Heinlein","year":"2004","unstructured":"Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25(2):276\u2013308. https:\/\/doi.org\/10.1210\/er.2002-0032","journal-title":"Endocr Rev"},{"issue":"15","key":"1582_CR79","doi-asserted-by":"publisher","first-page":"7812","DOI":"10.3390\/ijms22157812","volume":"22","author":"C Hernando","year":"2021","unstructured":"Hernando C, Ortega-Morillo B, Tapia M, Morag\u00f3n S, Mart\u00ednez MT, Eroles P, Garrido-Cano I, Adam-Artigues A, Lluch A, Bermejo B, Cejalvo JM (2021) Oral selective estrogen receptor degraders (SERDs) as a novel breast cancer therapy: present and future from a clinical perspective. Int J Mol Sci 22(15):7812. https:\/\/doi.org\/10.3390\/ijms22157812","journal-title":"Int J Mol Sci"},{"issue":"7\u20138","key":"1582_CR80","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.biocel.2007.02.009","volume":"39","author":"H Hess-Stumpp","year":"2007","unstructured":"Hess-Stumpp H, Bracker TU, Henderson D, Politz O (2007) MS-275, a potent orally available inhibitor of histone deacetylases\u2014the development of an anticancer agent. Int J Biochem Cell Biol 39(7\u20138):1388\u20131405. https:\/\/doi.org\/10.1016\/j.biocel.2007.02.009","journal-title":"Int J Biochem Cell Biol"},{"issue":"14","key":"1582_CR81","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1002\/cmdc.201800206","volume":"13","author":"NJ Hiller","year":"2018","unstructured":"Hiller NJ, e Silva Faria NAARX, Souza Resende ALAJALC, Borges Farias A, Correia Romeiro N, de Luna Martins D (2018) Synthesis and evaluation of the anticancer and trypanocidal activities of boronic tyrphostins. ChemMedChem 13(14):1395\u20131404. https:\/\/doi.org\/10.1002\/cmdc.201800206","journal-title":"ChemMedChem"},{"issue":"4","key":"1582_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.103047","volume":"299","author":"J Huang","year":"2023","unstructured":"Huang J, Liu X, Sun Y, Li Z, Lin MH, Hamilton K, Mandel CR, Sandmeir F, Conti E, Oyala PH, Tong L (2023) An examination of the metal ion content in the active sites of human endonucleases CPSF73 and INTS11. J Biol Chem 299(4):103047. https:\/\/doi.org\/10.1016\/j.jbc.2023.103047","journal-title":"J Biol Chem"},{"issue":"e14","key":"1582_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/erm.2022.7","volume":"24","author":"AM Hughes","year":"2022","unstructured":"Hughes AM (2022) Importance of radiobiological studies for the advancement of boron neutron capture therapy (BNCT). Expert Rev Mol Med 24(e14):1\u201311. https:\/\/doi.org\/10.1017\/erm.2022.7","journal-title":"Expert Rev Mol Med"},{"key":"1582_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202400622","volume":"20","author":"ML Introvigne","year":"2024","unstructured":"Introvigne ML, Destro L, Mologni L, Crippa V, Zardi P, Fini F, Prati F, Caselli E, Zambon A (2024) \u03b1-Triazolylboronic acids: a novel scaffold to target FLT3 in AML. ChemMedChem 20:e202400622. https:\/\/doi.org\/10.1002\/cmdc.202400622","journal-title":"ChemMedChem"},{"issue":"7","key":"1582_CR85","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1358\/dot.2006.42.7.985637","volume":"42","author":"SRD Johnston","year":"2006","unstructured":"Johnston SRD, Leary A (2006) Lapatinib: a novel EGFR\/HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc) 42(7):441. https:\/\/doi.org\/10.1358\/dot.2006.42.7.985637","journal-title":"Drugs Today (Barc)"},{"issue":"19","key":"1582_CR86","doi-asserted-by":"publisher","first-page":"5875","DOI":"10.1021\/jm0581821","volume":"48","author":"H Kagechika","year":"2005","unstructured":"Kagechika H, Shudo K (2005) Synthetic retinoids: recent developments concerning structure and clinical utility. J Med Chem 48(19):5875\u20135883. https:\/\/doi.org\/10.1021\/jm0581821","journal-title":"J Med Chem"},{"issue":"S1","key":"1582_CR87","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/pros.2990250709","volume":"25","author":"AV Kaisary","year":"1994","unstructured":"Kaisary AV (1994) Current clinical studies with a new nonsteroidal antiandrogen, Casodex. Prostate 25(S1):27\u201333. https:\/\/doi.org\/10.1002\/pros.2990250709","journal-title":"Prostate"},{"issue":"6","key":"1582_CR88","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","volume":"8","author":"RC Kane","year":"2003","unstructured":"Kane RC, Bross PF, Farrell AT, Pazdur R (2003) Velcade\u00ae: U.s. fda approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8(6):508\u2013513. https:\/\/doi.org\/10.1634\/theoncologist.8-6-508","journal-title":"Oncologist"},{"issue":"19","key":"1582_CR89","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.2174\/138161212800626193","volume":"18","author":"D Katsetos","year":"2012","unstructured":"Katsetos D, Draber P (2012) Tubulins as therapeutic targets in cancer: from bench to bedside. Curr Pharm des 18(19):2778\u20132792. https:\/\/doi.org\/10.2174\/138161212800626193","journal-title":"Curr Pharm des"},{"issue":"19","key":"1582_CR90","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1002\/cbic.202000131","volume":"21","author":"P Kavianpour","year":"2020","unstructured":"Kavianpour P, Gemmell MCM, Kahlert JU, Rendina LM (2020) Histone deacetylase 2 (HDAC2) inhibitors containing boron. ChemBioChem 21(19):2786\u20132791. https:\/\/doi.org\/10.1002\/cbic.202000131","journal-title":"ChemBioChem"},{"issue":"12","key":"1582_CR91","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.4161\/cc.8.12.8798","volume":"8","author":"A Kazi","year":"2009","unstructured":"Kazi A, Lawrence H, Guida WC, McLaughlin ML, Springett GM, Berndt N, Yip RM, Sebti SM (2009) Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells. Cell Cycle 8(12):1940\u20131951. https:\/\/doi.org\/10.4161\/cc.8.12.8798","journal-title":"Cell Cycle"},{"issue":"5","key":"1582_CR92","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s10787-021-00863-","volume":"29","author":"N Khalesi","year":"2021","unstructured":"Khalesi N, Korani S, Korani M, Johnston TP, Sahebkar A (2021) Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases. Inflammopharmacology 29(5):1291\u20131306. https:\/\/doi.org\/10.1007\/s10787-021-00863-","journal-title":"Inflammopharmacology"},{"issue":"7","key":"1582_CR93","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nsmb1105","volume":"13","author":"JA Khan","year":"2006","unstructured":"Khan JA, Tao X, Tong L (2006) Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat Struct Mol Biol 13(7):582\u2013588. https:\/\/doi.org\/10.1038\/nsmb1105","journal-title":"Nat Struct Mol Biol"},{"issue":"5","key":"1582_CR94","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1517\/14728222.11.5.695","volume":"11","author":"JA Khan","year":"2007","unstructured":"Khan JA, Forouhar F, Tao X, Tong L (2007) Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin Ther Targets 11(5):695\u2013705. https:\/\/doi.org\/10.1517\/14728222.11.5.695","journal-title":"Expert Opin Ther Targets"},{"key":"1582_CR95","doi-asserted-by":"publisher","DOI":"10.1039\/d5dt01667c","author":"T Kikani","year":"2025","unstructured":"Kikani T, Patel K, Thakore S (2025) Fluorophores to fighters: BODIPY-metal complexes as next-gen anticancer prodrugs. Dalton Trans Adv Article. https:\/\/doi.org\/10.1039\/d5dt01667c","journal-title":"Dalton Trans Adv Article"},{"issue":"1","key":"1582_CR96","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1006\/excr.1999.4706","volume":"253","author":"H Kim","year":"1999","unstructured":"Kim H, Muller WJ (1999) The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp Cell Res 253(1):78\u201387. https:\/\/doi.org\/10.1006\/excr.1999.4706","journal-title":"Exp Cell Res"},{"issue":"13","key":"1582_CR97","doi-asserted-by":"publisher","first-page":"8582","DOI":"10.1074\/jbc.m509043200","volume":"281","author":"AF Kisselev","year":"2006","unstructured":"Kisselev AF, Callard A, Goldberg AL (2006) Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem 281(13):8582\u20138590. https:\/\/doi.org\/10.1074\/jbc.m509043200","journal-title":"J Biol Chem"},{"issue":"14","key":"1582_CR98","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1093\/nar\/29.14.2905","volume":"29","author":"CM Klinge","year":"2001","unstructured":"Klinge CM (2001) Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 29(14):2905\u20132919. https:\/\/doi.org\/10.1093\/nar\/29.14.2905","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1582_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2005.03.033","volume":"235","author":"J Koivunen","year":"2006","unstructured":"Koivunen J, Aaltonen V, Peltonen J (2006) Protein Kinase C (PKC) family in cancer progression. Cancer Lett 235(1):1\u201310. https:\/\/doi.org\/10.1016\/j.canlet.2005.03.033","journal-title":"Cancer Lett"},{"key":"1582_CR100","doi-asserted-by":"crossref","unstructured":"Konstantinova IM, Tsimokha AS, Mittenberg AG (2008) Role of proteasomes in cellular regulation. In: International Review of Cell and Molecular Biology; Elsevier, pp 59\u2013124.","DOI":"10.1016\/S1937-6448(08)00602-3"},{"key":"1582_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108548","volume":"251","author":"S Kulkarni","year":"2023","unstructured":"Kulkarni S, Bhandary D, Singh Y, Monga V, Thareha S (2023) Boron in cancer therapeutics: an overview. Pharmacol Ther 251:108548. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108548","journal-title":"Pharmacol Ther"},{"issue":"5","key":"1582_CR102","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1158\/0008-5472.can-09-2766","volume":"70","author":"E Kupperman","year":"2010","unstructured":"Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F, Liu J, Blank J, Garcia K, Tsu C, Dick L, Fleming P, Yu L, Manfredi M, Rolfe M, Bolen J (2010) Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 70(5):1970\u20131980. https:\/\/doi.org\/10.1158\/0008-5472.can-09-2766","journal-title":"Cancer Res"},{"issue":"12","key":"1582_CR103","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.1021\/acs.jmedchem.5b00054","volume":"58","author":"A Lai","year":"2015","unstructured":"Lai A, Kahraman M, Govek S, Nagasawa J, Bonnefous C, Julien J, Douglas K, Sensintaffar J, Lu N, Lee KJ, Aparicio A, Kaufman J, Qian J, Shao G, Prudente R, Moon MJ, Joseph JD, Darimont B, Brigham D, Grillot K, Heyman R, Rix PJ, Hager JH, Smith ND (2015) Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts. J Med Chem 58(12):4888\u20134904. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b00054","journal-title":"J Med Chem"},{"issue":"10","key":"1582_CR104","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.2337\/diabetes.54.10.2988","volume":"54","author":"GR Lankas","year":"2005","unstructured":"Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T, Chan CC, Edmondson S, Feeney WP, He H, Ippolito DE, Kim D, Lyons KA, Ok HO, Patel RA, Petrov AN, Pryor KA, Qian X, Reigle L, Woods A, Wu JK, Zaller D, Zhang X, Zhu L, Weber AE, Thornberry NA (2005) Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes. Diabetes 54(10):2988\u20132994. https:\/\/doi.org\/10.2337\/diabetes.54.10.2988","journal-title":"Diabetes"},{"issue":"8","key":"1582_CR105","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1021\/acsmedchemlett.9b00252","volume":"10","author":"A Larcher","year":"2019","unstructured":"Larcher A, Nocentini A, Supuran CT, Winum JY, van der Lee A, Vasseur JJ, Laurencin D, Smietana M (2019) Bis-benzoxaboroles: design, synthesis, and biological evaluation as carbonic anhydrase inhibitors. ACS Med Chem Lett 10(8):1205\u20131210. https:\/\/doi.org\/10.1021\/acsmedchemlett.9b00252","journal-title":"ACS Med Chem Lett"},{"issue":"4","key":"1582_CR106","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3324\/haematol.2019.220657","volume":"105","author":"A Larocca","year":"2020","unstructured":"Larocca A, Mina R, Offidani M, Liberati AM, Ledda A, Patriarca F, Evangelista A, Spada S, Benevolo G, Oddolo D, Innao V, Cangiolosi C, Bernardini A, Musto P, Amico V, Fraticelli V, Paris L, Giuliani N, Falcone AP, Zambello R, De Paoli L, Romano A, Palumbo A, Montefusco V, H\u00e1jek R, Boccadoro M, Bringhen S (2020) First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. Haematologica 105(4):1074\u20131080. https:\/\/doi.org\/10.3324\/haematol.2019.220657","journal-title":"Haematologica"},{"issue":"16","key":"1582_CR107","doi-asserted-by":"publisher","first-page":"7290","DOI":"10.1021\/jm300740t","volume":"55","author":"MWJr Lee","year":"2012","unstructured":"Lee MWJr, Sevryugina YV, Khan A, Ye SQ (2012) Carboranes increase the potency of small molecule inhibitors of nicotinamide phosphoribosyltranferase. J Med Chem 55(16):7290\u20137294. https:\/\/doi.org\/10.1021\/jm300740t","journal-title":"J Med Chem"},{"issue":"11","key":"1582_CR108","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1016\/j.bmc.2016.04.025","volume":"24","author":"M Lei","year":"2016","unstructured":"Lei M, Feng H, Wang C, Li H, Shi J, Wang J, Liu Z, Chen S, Hu S, Zhu Y (2016) 3D-QSAR-aided design, synthesis, in vitro and in vivo evaluation of dipeptidyl boronic acid proteasome inhibitors and mechanism studies. Bioorg Med Chem 24(11):2576\u20132588. https:\/\/doi.org\/10.1016\/j.bmc.2016.04.025","journal-title":"Bioorg Med Chem"},{"issue":"2","key":"1582_CR109","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1042\/bj20021643","volume":"371","author":"B Leiting","year":"2003","unstructured":"Leiting B, Pryor KD, Wu JK, Marsilio F, Patel RA, Craik CS, Ellman JA, Cummings RT, Thornberry NA (2003) Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. Biochem J 371(2):525\u2013532. https:\/\/doi.org\/10.1042\/bj20021643","journal-title":"Biochem J"},{"issue":"1\u20132","key":"1582_CR110","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.epsl.2007.05.039","volume":"260","author":"E Lemarchand","year":"2007","unstructured":"Lemarchand E, Schott J, Gaillardet J (2007) How surface complexes impact boron isotope fractionation: evidence from Fe and Mn oxides sorption experiments. Earth Planet Sci Lett 260(1\u20132):277\u2013296. https:\/\/doi.org\/10.1016\/j.epsl.2007.05.039","journal-title":"Earth Planet Sci Lett"},{"issue":"15","key":"1582_CR111","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1242\/dev.091744","volume":"140","author":"S Lim","year":"2013","unstructured":"Lim S, Kaldis P (2013) Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development 140(15):3079\u20133093. https:\/\/doi.org\/10.1242\/dev.091744","journal-title":"Development"},{"issue":"9","key":"1582_CR112","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1021\/ar200126t","volume":"44","author":"AR Lippert","year":"2011","unstructured":"Lippert AR, Van de Bittner GC, Chang CJ (2011) Boronate oxidation as a bioorthogonal reaction approach for studying the chemistry of hydrogen peroxide in living systems. Acc Chem Res 44(9):793\u2013804. https:\/\/doi.org\/10.1021\/ar200126t","journal-title":"Acc Chem Res"},{"issue":"11","key":"1582_CR113","doi-asserted-by":"publisher","first-page":"9189","DOI":"10.1074\/jbc.m108335200","volume":"277","author":"H Liu","year":"2002","unstructured":"Liu H, Park WC, Bentrem DJ, McKian KP, Reyes ADL, Loweth JA, Schafer JM, Zapf JW, Jordan VC (2002) Structure-function relationships of the raloxifene-estrogen receptor-\u03b1 complex for regulating transforming growth factor-\u03b1 expression in breast cancer cells. J Biol Chem 277(11):9189\u20139198. https:\/\/doi.org\/10.1074\/jbc.m108335200","journal-title":"J Biol Chem"},{"issue":"17","key":"1582_CR114","doi-asserted-by":"publisher","first-page":"8134","DOI":"10.1021\/acs.jmedchem.6b00753","volume":"59","author":"J Liu","year":"2016","unstructured":"Liu J, Zheng S, Akerstrom VL, Yuan C, Ma Y, Zhong Q, Zhang C, Zhang Q, Guo S, Ma P, Skripnikova EV, Bratton MR, Pannuti A, Miele L, Wiese TE, Wang G (2016) Fulvestrant-3 boronic acid (ZB716): an orally bioavailable selective estrogen receptor downregulator (SERD). J Med Chem 59(17):8134\u20138140. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00753","journal-title":"J Med Chem"},{"issue":"1","key":"1582_CR115","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1021\/acsmedchemlett.6b00410","volume":"8","author":"J Liu","year":"2017","unstructured":"Liu J, Zheng S, Guo S, Zhang C, Zhong Q, Zhang Q, Ma P, Skripnikova EV, Bratton MR, Wiese TE, Wang G (2017) Rational design of a boron-modified triphenylethylene (GLL398) as an oral selective estrogen receptor downregulator. ACS Med Chem Lett 8(1):102\u2013106. https:\/\/doi.org\/10.1021\/acsmedchemlett.6b00410","journal-title":"ACS Med Chem Lett"},{"issue":"5","key":"1582_CR116","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.bmc.2018.01.017","volume":"26","author":"H Liu","year":"2018","unstructured":"Liu H, Wu J, Ge Y, Li A, Li J, Liu Z, Xu Y, Xu Q, Li Y (2018) Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors. Bioorg Med Chem 26(5):1050\u20131061. https:\/\/doi.org\/10.1016\/j.bmc.2018.01.017","journal-title":"Bioorg Med Chem"},{"issue":"8","key":"1582_CR117","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/cr.2016.86","volume":"26","author":"I Livneh","year":"2016","unstructured":"Livneh I, Cohen-Kaplan V, Cohen-Rosenzweig C, Avni N, Ciechanover A (2016) The life cycle of the 26S proteasome: from birth, through regulation and function, and onto its death. Cell Res 26(8):869\u2013885. https:\/\/doi.org\/10.1038\/cr.2016.86","journal-title":"Cell Res"},{"issue":"4","key":"1582_CR118","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.bbalip.2013.01.002","volume":"1831","author":"CC Lord","year":"2013","unstructured":"Lord CC, Thomas G, Brown JM (2013) Mammalian alpha beta hydrolase domain (ABHD) proteins: lipid metabolizing enzymes at the interface of cell signaling and energy metabolism. Biochimica Et Biophys Acta (BBA)\u2014Mol Cell Biol Lipids 1831(4):792\u2013802. https:\/\/doi.org\/10.1016\/j.bbalip.2013.01.002","journal-title":"Biochimica Et Biophys Acta (BBA)\u2014Mol Cell Biol Lipids"},{"issue":"1","key":"1582_CR119","doi-asserted-by":"publisher","DOI":"10.1186\/2050-7771-1-13","volume":"1","author":"S L\u00fc","year":"2013","unstructured":"L\u00fc S, Wang J (2013) The resistance mechanisms of proteasome inhibitor bortezomib. Biomark Res 1(1):13. https:\/\/doi.org\/10.1186\/2050-7771-1-13","journal-title":"Biomark Res"},{"issue":"14","key":"1582_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2020.127258","volume":"30","author":"L Luo","year":"2020","unstructured":"Luo L, Zhong Q, Guo S, Zhang C, Zhang Q, Zheng S, He L, Wang G (2020) Development of a bioavailable boron-containing PI-103 bioisostere, PI-103BE. Bioorg Med Chem Lett 30(14):127258. https:\/\/doi.org\/10.1016\/j.bmcl.2020.127258","journal-title":"Bioorg Med Chem Lett"},{"key":"1582_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2021.109770","volume":"351","author":"C Ma","year":"2022","unstructured":"Ma C, Liu M, Zhang J, Cai H, Wu Y, Zhang Y, Ji Y, Shan H, Zou Z, Yang L, Liu L, Xu H, Lei H, Liu C, Zhou L, Cao Y, Zhou H, Wu Y (2022) ZCL-082, a boron-containing compound, induces apoptosis of non-Hodgkin\u2019s lymphoma via targeting P90 ribosomal S6 kinase 1\/NF-\u03baB signaling pathway. Chem Biol Interact 351:109770. https:\/\/doi.org\/10.1016\/j.cbi.2021.109770","journal-title":"Chem Biol Interact"},{"issue":"20","key":"1582_CR122","doi-asserted-by":"publisher","first-page":"8378","DOI":"10.1021\/jm500827t","volume":"57","author":"DY Maeda","year":"2014","unstructured":"Maeda DY, Peck AM, Schuler AD, Quinn MT, Kirpotina LN, Wicomb WN, Fan GH, Zebala JA (2014) Discovery of 2-[5-(4-fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic acid (SX-517): noncompetitive boronic acid antagonist of CXCR1 and CXCR2. J Med Chem 57(20):8378\u20138397. https:\/\/doi.org\/10.1021\/jm500827t","journal-title":"J Med Chem"},{"issue":"11","key":"1582_CR123","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/j.bmcl.2015.04.041","volume":"25","author":"DY Maeda","year":"2015","unstructured":"Maeda DY, Peck AM, Schuler AD, Quinn MT, Kirpotina LN, Wicomb WN, Auten RL, Gundla R, Zebala JA (2015) Boronic acid-containing CXCR1\/2 antagonists: optimization of metabolic stability, in vivo evaluation, and a proposed receptor binding model. Bioorg Med Chem Lett 25(11):2280\u20132284. https:\/\/doi.org\/10.1016\/j.bmcl.2015.04.041","journal-title":"Bioorg Med Chem Lett"},{"issue":"10","key":"1582_CR124","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s40265-017-0776-3","volume":"77","author":"A Markham","year":"2017","unstructured":"Markham A (2017) Brigatinib: first global approval. Drugs 77(10):1131\u20131135. https:\/\/doi.org\/10.1007\/s40265-017-0776-3","journal-title":"Drugs"},{"key":"1582_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112670","volume":"207","author":"H Maslah","year":"2020","unstructured":"Maslah H, Skarbek C, Pethe S, Labru\u00e8re R (2020) Anticancer boron-containing prodrugs responsive to oxidative stress from the tumor microenvironment. Eur J Med Chem 207:112670. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112670","journal-title":"Eur J Med Chem"},{"issue":"5","key":"1582_CR126","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/bf02897908","volume":"8","author":"Y Matsuzaki","year":"2003","unstructured":"Matsuzaki Y, Sowa Y, Hirose T, Yokota T, Sakai T (2003) Histone deacetylase inhibitors \u2014promising agents for \u2018gene-regulating chemoprevention\u2019 and \u2018molecular-targeting prevention\u2019 of cancer. Environ Health Prev Med 8(5):157\u2013160. https:\/\/doi.org\/10.1007\/bf02897908","journal-title":"Environ Health Prev Med"},{"issue":"5","key":"1582_CR127","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1124\/mi.3.5.281","volume":"3","author":"J Matthews","year":"2003","unstructured":"Matthews J (2003) Estrogen signaling: a subtle balance between ER and ER. Mol Interv 3(5):281\u2013292. https:\/\/doi.org\/10.1124\/mi.3.5.281","journal-title":"Mol Interv"},{"key":"1582_CR128","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/20459","volume":"399","author":"PH Maxwell","year":"1999","unstructured":"Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271\u2013275. https:\/\/doi.org\/10.1038\/20459","journal-title":"Nature"},{"issue":"1","key":"1582_CR129","doi-asserted-by":"publisher","DOI":"10.3390\/metabo8010019","volume":"8","author":"M Mboge","year":"2018","unstructured":"Mboge M, Mahon B, McKenna R, Frost S (2018) Carbonic anhydrases: role in pH control and cancer. Metabolites 8(1):19. https:\/\/doi.org\/10.3390\/metabo8010019","journal-title":"Metabolites"},{"issue":"8","key":"1582_CR130","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.clinthera.2008.08.008","volume":"30","author":"P Medina","year":"2008","unstructured":"Medina P, Goodin S (2008) Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 30(8):1426\u20131447. https:\/\/doi.org\/10.1016\/j.clinthera.2008.08.008","journal-title":"Clin Ther"},{"key":"1582_CR131","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/ph15030264","volume":"15","author":"K Messner","year":"2022","unstructured":"Messner K, Vuong B, Tranmer GK (2022) The boron advantage: the evolution and diversification of boron\u2019s applications in medicinal chemistry. Pharmaceuticals 15:264. https:\/\/doi.org\/10.3390\/ph15030264","journal-title":"Pharmaceuticals"},{"key":"1582_CR132","doi-asserted-by":"publisher","unstructured":"Mey J (2017) RAR\/RXR\u2010mediated signaling. Gene regulation, epigenetics and hormone signaling. Wiley, Hoboken, pp 457\u2013510. https:\/\/doi.org\/10.1002\/9783527697274.ch16.","DOI":"10.1002\/9783527697274.ch16"},{"issue":"10","key":"1582_CR133","doi-asserted-by":"publisher","first-page":"4859","DOI":"10.1039\/c4nj00612g","volume":"38","author":"P Milani","year":"2014","unstructured":"Milani P, Demasi M, de Rezende L, Amaral AT, Andrade LH (2014) Synthesis of l-cysteine-based boron compounds and their evaluation as proteasome inhibitors. New J Chem 38(10):4859\u20134871. https:\/\/doi.org\/10.1039\/c4nj00612g","journal-title":"New J Chem"},{"issue":"8","key":"1582_CR134","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc1143","volume":"3","author":"GB Mills","year":"2003","unstructured":"Mills GB, Moolenaar WH (2003) The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3(8):582\u2013591. https:\/\/doi.org\/10.1038\/nrc1143","journal-title":"Nat Rev Cancer"},{"issue":"18","key":"1582_CR135","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1021\/jm970109q","volume":"40","author":"H Miyachi","year":"1997","unstructured":"Miyachi H, Azuma A, Ogasawara A, Uchimura E, Watanabe N, Kobayashi Y, Kato F, Kato M, Hashimoto Y (1997) Novel biological response modifiers: phthalimides with tumor necrosis factor-\u03b1 production-regulating activity. J Med Chem 40(18):2858\u20132865. https:\/\/doi.org\/10.1021\/jm970109q","journal-title":"J Med Chem"},{"key":"1582_CR136","doi-asserted-by":"publisher","first-page":"20827","DOI":"10.1021\/acs.jmedchem.4c02309","volume":"67","author":"SN Mlynarski","year":"2024","unstructured":"Mlynarski SN, Aquila BM, Cantin S, Cook S, Doshi A, Finlay RV, Gangl ET, Grebe T, Gu C, Kawatkar SP, Petersen J, Pop-Damkov P, Schuller AG, Shao W, Shields JD, Simpson I, Tavakoli S, Tentarelli S, Throner S, Wang H, Wang J, Wu D, Ye Q (2024) Discovery of (2R,4R)-4-((S)-2-amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic acid (AZD0011), an actively transported prodrug of a potent arginase inhibitor to treat cancer. J Med Chem 67:20827\u201320841. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02309","journal-title":"J Med Chem"},{"issue":"12","key":"1582_CR137","doi-asserted-by":"publisher","first-page":"997","DOI":"10.7164\/antibiotics.54.997","volume":"54","author":"I Momose","year":"2001","unstructured":"Momose I, Sekizawa R, Hashizume H, Kinoshita N, Homma Y, Hamada M, Iinuma H, Takeuchi T (2001a) Tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp. MK993-dF2. i. Taxonomy, isolation, physico-chemical properties and biological activities. J Antibiot 54(12):997\u20131003. https:\/\/doi.org\/10.7164\/antibiotics.54.997","journal-title":"J Antibiot"},{"issue":"12","key":"1582_CR138","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.7164\/antibiotics.54.1004","volume":"54","author":"I Momose","year":"2001","unstructured":"Momose I, Sekizawa R, Hirosawa S, Ikeda D, Naganawa H, Iinuma H, Takeuchi T (2001b) Tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp. MK993-dF2. ii. Structure determination and synthesis. J Antibiot 54(12):1004\u20131012. https:\/\/doi.org\/10.7164\/antibiotics.54.1004","journal-title":"J Antibiot"},{"issue":"9","key":"1582_CR139","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1271\/bbb.69.1733","volume":"69","author":"I Momose","year":"2005","unstructured":"Momose I, Umezawa Y, Hirosawa S, Iijima M, Iinuma H, Ikeda D (2005) Synthesis and activity of tyropeptin A derivatives as potent and selective inhibitors of mammalian 20S proteasome. Biosci Biotechnol Biochem 69(9):1733\u20131742. https:\/\/doi.org\/10.1271\/bbb.69.1733","journal-title":"Biosci Biotechnol Biochem"},{"issue":"12","key":"1582_CR140","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1111\/cas.12542","volume":"105","author":"I Momose","year":"2014","unstructured":"Momose I, Abe H, Watanabe T, Ohba SI, Yamazaki K, Dan S, Yamori T, Masuda T, Nomoto A (2014) Antitumor effects of tyropeptin-boronic acid derivatives: new proteasome inhibitors. Cancer Sci 105(12):1609\u20131615. https:\/\/doi.org\/10.1111\/cas.12542","journal-title":"Cancer Sci"},{"issue":"18","key":"1582_CR141","doi-asserted-by":"publisher","first-page":"5609","DOI":"10.1158\/1078-0432.ccr-08-2762","volume":"15","author":"YP Moss\u00e9","year":"2009","unstructured":"Moss\u00e9 YP, Wood A, Maris JM (2009) Inhibition of ALK signaling for cancer therapy. Clin Cancer Res 15(18):5609\u20135614. https:\/\/doi.org\/10.1158\/1078-0432.ccr-08-2762","journal-title":"Clin Cancer Res"},{"key":"1582_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118224","volume":"301","author":"A Nagar","year":"2026","unstructured":"Nagar A, Sarkar D, Bardiya R, Shirkhedkar A, Soni V, Sonawane S, Chaudhari P, Talukdar A (2026) Benzoxaboroles in medicinal chemistry: a structure-guided perspective on next-generation therapeutics. Eur J Med Chem 301:118224. https:\/\/doi.org\/10.1016\/j.ejmech.2025.118224","journal-title":"Eur J Med Chem"},{"issue":"7","key":"1582_CR143","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/cmdc.200600068","volume":"1","author":"H Nakamura","year":"2006","unstructured":"Nakamura H, Kuroda H, Saito H, Suzuki R, Yamori T, Maruyama K, Haga T (2006) Synthesis and biological evaluation of boronic acid containing cis-stilbenes as apoptotic tubulin polymerization inhibitors. ChemMedChem 1(7):729\u2013740. https:\/\/doi.org\/10.1002\/cmdc.200600068","journal-title":"ChemMedChem"},{"issue":"12","key":"1582_CR144","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1016\/j.bmcl.2009.04.103","volume":"19","author":"H Nakamura","year":"2009","unstructured":"Nakamura H, Watanabe M, Ban HS, Nabeyama W, Asai A (2009) Synthesis and biological evaluation of boron peptide analogues of belactosin C as proteasome inhibitors. Bioorg Med Chem Lett 19(12):3220\u20133224. https:\/\/doi.org\/10.1016\/j.bmcl.2009.04.103","journal-title":"Bioorg Med Chem Lett"},{"issue":"12","key":"1582_CR145","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.1074\/jbc.m117.775684","volume":"292","author":"M Nakano","year":"2017","unstructured":"Nakano M, Fukami T, Gotoh S, Nakajima M (2017) A-to-I RNA editing up-regulates human dihydrofolate reductase in breast cancer. J Biol Chem 292(12):4873\u20134884. https:\/\/doi.org\/10.1074\/jbc.m117.775684","journal-title":"J Biol Chem"},{"issue":"1","key":"1582_CR146","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40487-017-0046-2","volume":"5","author":"MR Nathan","year":"2017","unstructured":"Nathan MR, Schmid P (2017) A review of fulvestrant in breast cancer. Oncol Ther 5(1):17\u201329. https:\/\/doi.org\/10.1007\/s40487-017-0046-2","journal-title":"Oncol Ther"},{"issue":"24","key":"1582_CR147","doi-asserted-by":"publisher","first-page":"11658","DOI":"10.1158\/0008-5472.can-05-2370","volume":"65","author":"ST Nawrocki","year":"2005","unstructured":"Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner KJr, Huang P, Abbruzzese JL, McConkey DJ (2005) Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 65(24):11658\u201311666. https:\/\/doi.org\/10.1158\/0008-5472.can-05-2370","journal-title":"Cancer Res"},{"issue":"5","key":"1582_CR148","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1021\/acs.jmedchem.6b00975","volume":"60","author":"KM Nelson","year":"2017","unstructured":"Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA (2017) The essential medicinal chemistry of curcumin: miniperspective. J Med Chem 60(5):1620\u20131637. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00975","journal-title":"J Med Chem"},{"issue":"6","key":"1582_CR149","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/13543776.2018.1473379","volume":"28","author":"A Nocentini","year":"2018","unstructured":"Nocentini A, Supuran CT, Winum JY (2018) Benzoxaborole compounds for therapeutic uses: a patent review (2010\u20132018). Expert Opin Ther Pat 28(6):493\u2013504. https:\/\/doi.org\/10.1080\/13543776.2018.1473379","journal-title":"Expert Opin Ther Pat"},{"key":"1582_CR150","doi-asserted-by":"publisher","first-page":"8118","DOI":"10.1021\/acs.jmedchem.3c00433","volume":"66","author":"A Nocentini","year":"2023","unstructured":"Nocentini A, Bonardi A, Bazzicalupi C, Alterio V, Esposito D, Monti SM, Smietana M, Simone GD, Supuran CT, Gratteri P, Winum JY (2023) 6-substituted triazolyl benzoxaboroles as selective carbonic anhydrase inhibitors. In silico design, synthesis, and X-ray crystallography. J Med Chem 66:8118\u20138129. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00433","journal-title":"J Med Chem"},{"issue":"5","key":"1582_CR151","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1248\/bpb.21.544","volume":"21","author":"K Ohta","year":"1998","unstructured":"Ohta K, Tsuji M, Kawachi E, Fukasawa H, Hashimoto Y, Shudo K, Kagechika H (1998) Potent retinoid synergists with a diphenylamine skeleton. Biol Pharm Bull 21(5):544\u2013546. https:\/\/doi.org\/10.1248\/bpb.21.544","journal-title":"Biol Pharm Bull"},{"issue":"23","key":"1582_CR152","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.1016\/j.bmcl.2004.09.035","volume":"14","author":"K Ohta","year":"2004","unstructured":"Ohta K, Iijima T, Kawachi E, Kagechika H, Endo Y (2004) Novel retinoid X receptor (RXR) antagonists having a dicarba-closo-dodecaborane as a hydrophobic moiety. Bioorg Med Chem Lett 14(23):5913\u20135918. https:\/\/doi.org\/10.1016\/j.bmcl.2004.09.035","journal-title":"Bioorg Med Chem Lett"},{"issue":"17","key":"1582_CR153","doi-asserted-by":"publisher","first-page":"8022","DOI":"10.1016\/j.bmc.2008.07.055","volume":"16","author":"K Ohta","year":"2008","unstructured":"Ohta K, Goto T, Fijii S, Suzuki T, Ohta S, Endo Y (2008) Design and synthesis of carborane-containing androgen receptor (AR) antagonist bearing a pyridine ring. Bioorg Med Chem 16(17):8022\u20138028. https:\/\/doi.org\/10.1016\/j.bmc.2008.07.055","journal-title":"Bioorg Med Chem"},{"issue":"10\u201312","key":"1582_CR154","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1080\/15257770701548733","volume":"26","author":"A Olejniczak","year":"2007","unstructured":"Olejniczak A, Wojtczak B, Lesnikowski ZJ (2007) 2\u2032-deoxyadenosine bearing hydrophobic carborane pharmacophore. Nucleosides Nucleotides Nucleic Acids 26(10\u201312):1611\u20131613. https:\/\/doi.org\/10.1080\/15257770701548733","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"1582_CR155","doi-asserted-by":"publisher","DOI":"10.1007\/s12013-025-01885-1","author":"FC Onder","year":"2025","unstructured":"Onder FC, Ural K, Onder A, Ozpolat B, Ay M (2025) Boron containing curcumin-like compound as an acetylcholinesterase inhibitor and anticancer agent: synthesis, biological evaluation, and computational insights. Cell Biochem Biophys. https:\/\/doi.org\/10.1007\/s12013-025-01885-1","journal-title":"Cell Biochem Biophys"},{"issue":"12","key":"1582_CR156","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11122002","volume":"11","author":"KL Owen","year":"2019","unstructured":"Owen KL, Brockwell NK, Parker BS (2019) JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression. Cancers (Basel) 11(12):2002. https:\/\/doi.org\/10.3390\/cancers11122002","journal-title":"Cancers (Basel)"},{"key":"1582_CR157","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/s41417-024-00770-y","volume":"31","author":"G Pagani","year":"2024","unstructured":"Pagani G, Gandellini P (2024) Cleavage and polyadenylation machinery as a novel targetable vulnerability for human cancer. Cancer Gene Ther 31:957\u2013960. https:\/\/doi.org\/10.1038\/s41417-024-00770-y","journal-title":"Cancer Gene Ther"},{"issue":"12","key":"1582_CR158","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s40265-018-0952-0","volume":"78","author":"J Paik","year":"2018","unstructured":"Paik J, Dhillon S (2018) Alectinib: a review in advanced, ALK-positive NSCLC. Drugs 78(12):1247\u20131257. https:\/\/doi.org\/10.1007\/s40265-018-0952-0","journal-title":"Drugs"},{"issue":"8","key":"1582_CR159","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.tips.2006.06.005","volume":"27","author":"V Papadopoulos","year":"2006","unstructured":"Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacap\u00e8re JJ, Lindemann P, Norenberg MD, Nutt D, Weizman A, Zhang MR, Gavish M (2006) Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 27(8):402\u2013409. https:\/\/doi.org\/10.1016\/j.tips.2006.06.005","journal-title":"Trends Pharmacol Sci"},{"issue":"15","key":"1582_CR160","doi-asserted-by":"publisher","first-page":"5036","DOI":"10.1158\/0008-5472.can-03-2707","volume":"64","author":"CN Papandreou","year":"2004","unstructured":"Papandreou CN, Logothetis CJ (2004) Bortezomib as a potential treatment for prostate cancer. Cancer Res 64(15):5036\u20135043. https:\/\/doi.org\/10.1158\/0008-5472.can-03-2707","journal-title":"Cancer Res"},{"issue":"8","key":"1582_CR161","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrd1159","volume":"2","author":"A Paramore","year":"2003","unstructured":"Paramore A, Frantz S (2003) Bortezomib. Nat Rev Drug Discov 2(8):611\u2013612. https:\/\/doi.org\/10.1038\/nrd1159","journal-title":"Nat Rev Drug Discov"},{"issue":"16","key":"1582_CR162","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1182\/blood-2009-05-223677","volume":"114","author":"F Parlati","year":"2009","unstructured":"Parlati F, Lee SJ, Aujay M, Suzuki E, Levitsky K, Lorens JB, Micklem DR, Ruurs P, Sylvain C, Lu Y, Shenk KD, Bennett MK (2009) Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 114(16):3439\u20133447. https:\/\/doi.org\/10.1182\/blood-2009-05-223677","journal-title":"Blood"},{"issue":"7","key":"1582_CR163","doi-asserted-by":"publisher","first-page":"685","DOI":"10.2174\/138161208783877893","volume":"14","author":"J Pastorek","year":"2008","unstructured":"Pastorek J, Pastorekova S, Zatovicova M (2008) Cancer-associated carbonic anhydrases and their inhibition. Curr Pharm des 14(7):685\u2013698. https:\/\/doi.org\/10.2174\/138161208783877893","journal-title":"Curr Pharm des"},{"issue":"3","key":"1582_CR164","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/14756360410001689540","volume":"19","author":"S Pastorekova","year":"2004","unstructured":"Pastorekova S, Parkkila S, Pastorek J, Supuran CT (2004) Review article. J Enzyme Inhib Med Chem 19(3):199\u2013229. https:\/\/doi.org\/10.1080\/14756360410001689540","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"9","key":"1582_CR165","doi-asserted-by":"publisher","first-page":"7630","DOI":"10.1074\/jbc.m211129200","volume":"278","author":"ST Pearce","year":"2003","unstructured":"Pearce ST, Liu H, Jordan VC (2003) Modulation of estrogen receptor \u03b1 function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12. J Biol Chem 278(9):7630\u20137638. https:\/\/doi.org\/10.1074\/jbc.m211129200","journal-title":"J Biol Chem"},{"issue":"5","key":"1582_CR166","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1182\/blood-2007-07-100651","volume":"111","author":"R Piva","year":"2008","unstructured":"Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, Giai V, Coscia M, Peola S, Massaia M, Pezzoni G, Allievi C, Pescalli N, Cassin M, di Giovine S, Nicoli P, de Feudis P, Strepponi I, Roato I, Ferracini R, Bussolati B, Camussi G, Jones-Bolin S, Hunter K, Zhao H, Neri A, Palumbo A, Berkers C, Ovaa H, Bernareggi A, Inghirami G (2008) CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 111(5):2765\u20132775. https:\/\/doi.org\/10.1182\/blood-2007-07-100651","journal-title":"Blood"},{"issue":"8","key":"1582_CR167","first-page":"721","volume":"2","author":"JA Plumb","year":"2003","unstructured":"Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, La Thangue NB, Brown R (2003) Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2(8):721\u2013728","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1582_CR168","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/sj.bjc.6600936","volume":"89","author":"CPS Potter","year":"2003","unstructured":"Potter CPS, Harris AL (2003) Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 89(1):2\u20137. https:\/\/doi.org\/10.1038\/sj.bjc.6600936","journal-title":"Br J Cancer"},{"key":"1582_CR169","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1021\/cr00081a005","volume":"87","author":"DM Quinn","year":"1987","unstructured":"Quinn DM (1987) Acetylcholinesterase: enzyme structure, reaction dynamics, and virtual transition states. Chem Rev 87:955\u2013979. https:\/\/doi.org\/10.1021\/cr00081a005","journal-title":"Chem Rev"},{"key":"1582_CR170","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117788","volume":"182","author":"J Rataj","year":"2025","unstructured":"Rataj J, Gorecki L, Muthna D, Sorf A, Krystof V, Klener P, Ceckova M, Rezacova M, Korabecny J (2025) Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: novel molecular approaches and therapeutic challenges. Biomed Pharmacother 182:117788. https:\/\/doi.org\/10.1016\/j.biopha.2024.117788","journal-title":"Biomed Pharmacother"},{"issue":"13","key":"1582_CR171","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1128\/mcb.25.13.5675-5686.2005","volume":"25","author":"RR Raval","year":"2005","unstructured":"Raval RR, Lau KW, Tran MGB, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25(13):5675\u20135686. https:\/\/doi.org\/10.1128\/mcb.25.13.5675-5686.2005","journal-title":"Mol Cell Biol"},{"issue":"2","key":"1582_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2019.115236","volume":"28","author":"J Ren","year":"2020","unstructured":"Ren J, Shi W, Zhao D, Wang Q, Chang X, He X, Wang X, Gao Y, Lu P, Zhang X, Xu H, Zhang Y (2020) Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors. Bioorg Med Chem 28(2):115236. https:\/\/doi.org\/10.1016\/j.bmc.2019.115236","journal-title":"Bioorg Med Chem"},{"key":"1582_CR173","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2022.117071","volume":"75","author":"J Ren","year":"2022","unstructured":"Ren J, Gao Y, Shi W, Xu S, Wang Q, Zhao D, Kong L, Song W, Wang X, Zhang Y, He X, Wang Y, Tong S, Lu P, Li Y, Xu H, Zhang Y (2022) Design and synthesis of boron-containing ALK inhibitor with favorable in vivo efficacy. Bioorg Med Chem 75:117071. https:\/\/doi.org\/10.1016\/j.bmc.2022.117071","journal-title":"Bioorg Med Chem"},{"issue":"14","key":"1582_CR174","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.1021\/jm0701977","volume":"50","author":"RC Reynolds","year":"2007","unstructured":"Reynolds RC, Campbell SR, Fairchild RG, Kisliuk RL, Micca PL, Queener SF, Riordan JM, Sedwick WD, Waud WR, Leung, Dixon RW, Suling WJ, Borhani DW (2007) Novel boron-containing, nonclassical antifolates: synthesis and preliminary biological and structural evaluation. J Med Chem 50(14):3283\u20133289. https:\/\/doi.org\/10.1021\/jm0701977","journal-title":"J Med Chem"},{"issue":"6","key":"1582_CR175","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/j.1365-2141.2008.07573.x","volume":"144","author":"PG Richardson","year":"2009","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Blad\u00e9 J, Boccadoro M, Cavenagh JD, Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, San Miguel J (2009) Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 144(6):895\u2013903. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07573.x","journal-title":"Br J Haematol"},{"issue":"1","key":"1582_CR176","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1006\/bcmd.2000.0376","volume":"27","author":"VM Richon","year":"2001","unstructured":"Richon VM, Zhou X, Rifkind RA, Marks PA (2001) Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol Dis 27(1):260\u2013264. https:\/\/doi.org\/10.1006\/bcmd.2000.0376","journal-title":"Blood Cells Mol Dis"},{"key":"1582_CR177","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","volume":"100","author":"R Roskoski Jr","year":"2015","unstructured":"Roskoski R Jr (2015) A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res 100:1\u201323. https:\/\/doi.org\/10.1016\/j.phrs.2015.07.010","journal-title":"Pharmacol Res"},{"issue":"42","key":"1582_CR178","doi-asserted-by":"publisher","first-page":"10012","DOI":"10.1002\/ange.201102967","volume":"123","author":"M Rusch","year":"2011","unstructured":"Rusch M, Zimmermann TJ, B\u00fcrger M, Dekker FJ, G\u00f6rmer K, Triola G, Brockmeyer A, Janning P, B\u00f6ttcher T, Sieber SA, Vetter IR, Hedberg C, Waldmann H (2011) Identification of acyl protein thioesterases 1 and 2 as the cellular targets of the Ras-signaling modulators palmostatin B and M. Angew Chem Weinheim Bergstr Ger 123(42):10012\u201310016. https:\/\/doi.org\/10.1002\/ange.201102967","journal-title":"Angew Chem Weinheim Bergstr Ger"},{"issue":"49","key":"1582_CR179","doi-asserted-by":"publisher","first-page":"34940","DOI":"10.1074\/jbc.274.49.34940","volume":"274","author":"LC Sambucetti","year":"1999","unstructured":"Sambucetti LC, Fischer DD, Zabludoff S, Kwon PO, Chamberlin H, Trogani N, Xu H, Cohen D (1999) Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 274(49):34940\u201334947. https:\/\/doi.org\/10.1074\/jbc.274.49.34940","journal-title":"J Biol Chem"},{"issue":"1","key":"1582_CR180","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1634\/theoncologist.11-1-51","volume":"11","author":"J San Miguel","year":"2006","unstructured":"San Miguel J, Blad\u00e9 J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, Lonial S, Orlowski RZ, Sonneveld P, Ludwig H (2006) A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 11(1):51\u201361. https:\/\/doi.org\/10.1634\/theoncologist.11-1-51","journal-title":"Oncologist"},{"issue":"4","key":"1582_CR181","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/j.1365-2141.2009.08008.x","volume":"148","author":"E Sanchez","year":"2010","unstructured":"Sanchez E, Li M, Steinberg JA, Wang C, Shen J, Bonavida B, Li ZW, Chen H, Berenson JR (2010) The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. Br J Haematol 148(4):569\u2013581. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.08008.x","journal-title":"Br J Haematol"},{"issue":"8","key":"1582_CR182","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1002\/cmdc.201402075","volume":"9","author":"K Scarbaci","year":"2014","unstructured":"Scarbaci K, Troiano V, Ettari R, Pinto A, Micale N, Di Giovanni C, Cerchia C, Schirmeister T, Novellino E, Lavecchia A, Zappal\u00e0 M, Grasso S (2014) Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents. ChemMedChem 9(8):1801\u20131816. https:\/\/doi.org\/10.1002\/cmdc.201402075","journal-title":"ChemMedChem"},{"issue":"18","key":"1582_CR183","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202314143","volume":"63","author":"D Schauenburg","year":"2024","unstructured":"Schauenburg D, Gao B, Rochet LNC, Sch\u00fcler D, Coelho JAS, Ng DYW, Chudasama V, Kuan SL, Weil T (2024) Macrocyclic dual-locked \u201cturn-on\u201d drug for selective and traceless release in cancer cells. Angew Chem Int Ed 63(18):e202314143. https:\/\/doi.org\/10.1002\/anie.202314143","journal-title":"Angew Chem Int Ed"},{"key":"1582_CR184","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.3816\/clc.2005.s.008","volume":"7","author":"DP Schenkein","year":"2005","unstructured":"Schenkein DP (2005) Preclinical data with bortezomib in lung cancer. Clin Lung Cancer 7:S49\u2013S55. https:\/\/doi.org\/10.3816\/clc.2005.s.008","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"1582_CR185","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev.biophys.33.110502.133613","volume":"33","author":"JR Schnell","year":"2004","unstructured":"Schnell JR, Dyson HJ, Wright PE (2004) Structure, dynamics, and catalytic function of dihydrofolate reductase. Annu Rev Biophys Biomol Struct 33(1):119\u2013140. https:\/\/doi.org\/10.1146\/annurev.biophys.33.110502.133613","journal-title":"Annu Rev Biophys Biomol Struct"},{"issue":"18","key":"1582_CR186","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1016\/j.bmcl.2015.07.090","volume":"25","author":"AD Schuler","year":"2015","unstructured":"Schuler AD, Engles CA, Maeda DY, Quinn MT, Kirpotina LN, Wicomb WN, Mason SN, Auten RL, Zebala JA (2015) Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1\/2 antagonists: optimization of aqueous solubility and oral bioavailability. Bioorg Med Chem Lett 25(18):3793\u20133797. https:\/\/doi.org\/10.1016\/j.bmcl.2015.07.090","journal-title":"Bioorg Med Chem Lett"},{"issue":"13","key":"1582_CR187","doi-asserted-by":"publisher","first-page":"9330","DOI":"10.1021\/acs.jmedchem.1c00555","volume":"64","author":"D Sedl\u00e1k","year":"2021","unstructured":"Sedl\u00e1k D, Wilson TA, Tjarks W, Radomska HS, Wang H, Kolla JN, Le\u015bnikowski ZJ, \u0160pi\u010d\u00e1kov\u00e1 A, Ali T, Ishita K, Rakotondraibe LH, Vibhute S, Wang D, Anzenbacher P, Bennett C, Bartunek P, Coss CC (2021) Structure-activity relationship of para-carborane selective estrogen receptor \u03b2 agonists. J Med Chem 64(13):9330\u20139353. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00555","journal-title":"J Med Chem"},{"issue":"10","key":"1582_CR188","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nrc1187","volume":"3","author":"GL Semenza","year":"2003","unstructured":"Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721\u2013732. https:\/\/doi.org\/10.1038\/nrc1187","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1582_CR189","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/14756360701425014","volume":"22","author":"P Shah","year":"2007","unstructured":"Shah P, Westwell AD (2007) The role of fluorine in medicinal chemistry: review article. J Enzyme Inhib Med Chem 22(5):527\u2013540. https:\/\/doi.org\/10.1080\/14756360701425014","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"2","key":"1582_CR190","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/nejmoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santab\u00e1rbara P, Seymour L (2005) Erlotinib in previously treated non\u2013small-cell lung cancer. N Engl J Med 353(2):123\u2013132. https:\/\/doi.org\/10.1056\/nejmoa050753","journal-title":"N Engl J Med"},{"issue":"8","key":"1582_CR191","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1016\/j.bmcl.2016.03.007","volume":"26","author":"J Shi","year":"2016","unstructured":"Shi J, Lei M, Wu W, Feng H, Wang J, Chen S, Zhu Y, Hu S, Liu Z, Jiang C (2016) Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from \u0391\u03b1- and \u0391\u03b2-amino acids. Bioorg Med Chem Lett 26(8):1958\u20131962. https:\/\/doi.org\/10.1016\/j.bmcl.2016.03.007","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"1582_CR192","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.bmcl.2009.12.037","volume":"20","author":"K Shimizu","year":"2010","unstructured":"Shimizu K, Maruyama M, Yasui Y, Minegishi H, Ban HS, Nakamura H (2010) Boron-containing phenoxyacetanilide derivatives as hypoxia-inducible factor (HIF)-1\u03b1 inhibitors. Bioorg Med Chem Lett 20(4):1453\u20131456. https:\/\/doi.org\/10.1016\/j.bmcl.2009.12.037","journal-title":"Bioorg Med Chem Lett"},{"issue":"7","key":"1582_CR193","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1158\/1078-0432.ccr-08-2387","volume":"15","author":"S Singh","year":"2009","unstructured":"Singh S, Sadanandam A, Nannuru KC, Varney ML, Mayer-Ezell R, Bond R, Singh RK (2009) Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clin Cancer Res 15(7):2380\u20132386. https:\/\/doi.org\/10.1158\/1078-0432.ccr-08-2387","journal-title":"Clin Cancer Res"},{"key":"1582_CR194","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108224","volume":"156","author":"P Singh","year":"2025","unstructured":"Singh P, Arifuddin M, Supuran CT, Nerella SG (2025) Carbonic anhydrase inhibitors: structural insights and therapeutic potential. Bioorg Chem 156:108224. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108224","journal-title":"Bioorg Chem"},{"key":"1582_CR195","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.1007\/s00277-025-06671-w","volume":"104","author":"F Song","year":"2025","unstructured":"Song F, Su L, Gao S (2025) Impact of FLT3 mutation on its intracellular localization and implications for anti-leukemia strategy. Ann Hematol 104:4347\u20134356. https:\/\/doi.org\/10.1007\/s00277-025-06671-w","journal-title":"Ann Hematol"},{"key":"1582_CR196","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/35067589","volume":"2","author":"H Soreq","year":"2021","unstructured":"Soreq H, Seidman S (2021) Acetylcholinesterase \u2013new roles for an old actor. Nat Rev Neurosci 2:294\u2013302. https:\/\/doi.org\/10.1038\/35067589","journal-title":"Nat Rev Neurosci"},{"issue":"48","key":"1582_CR197","doi-asserted-by":"publisher","first-page":"46265","DOI":"10.1074\/jbc.m207135200","volume":"277","author":"J Stamos","year":"2002","unstructured":"Stamos J, Sliwkowski MX, Eigenbrot C (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277(48):46265\u201346272. https:\/\/doi.org\/10.1074\/jbc.m207135200","journal-title":"J Biol Chem"},{"key":"1582_CR198","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202300094","volume":"18","author":"P Stockmann","year":"2023","unstructured":"Stockmann P, Kuhnert L, Z\u00f6rner L, Honscha W, Hey-Hawkins E (2023) 2-carboranylquinazoline: the path to an ABCG2 inhibitor. ChemMedChem 18:e202300094. https:\/\/doi.org\/10.1002\/cmdc.202300094","journal-title":"ChemMedChem"},{"issue":"9","key":"1582_CR199","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2174\/156802607780636690","volume":"7","author":"C Supuran","year":"2007","unstructured":"Supuran C (2007) Carbonic anhydrases as drug targets - an overview. Curr Top Med Chem 7(9):825\u2013833. https:\/\/doi.org\/10.2174\/156802607780636690","journal-title":"Curr Top Med Chem"},{"issue":"2","key":"1582_CR200","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrd2467","volume":"7","author":"CT Supuran","year":"2008","unstructured":"Supuran CT (2008) Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 7(2):168\u2013181. https:\/\/doi.org\/10.1038\/nrd2467","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"1582_CR201","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1021\/jm900125m","volume":"52","author":"N Suzuki","year":"2009","unstructured":"Suzuki N, Suzuki T, Ota Y, Nakano T, Kurihara M, Okuda H, Yamori T, Tsumoto H, Nakagawa H, Miyata N (2009) Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors. J Med Chem 52(9):2909\u20132922. https:\/\/doi.org\/10.1021\/jm900125m","journal-title":"J Med Chem"},{"issue":"6","key":"1582_CR202","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.ejca.2006.01.012","volume":"42","author":"P Szlosarek","year":"2006","unstructured":"Szlosarek P, Charles KA, Balkwill FR (2006) Tumour necrosis factor-\u03b1 as a tumour promoter. Eur J Cancer 42(6):745\u2013750. https:\/\/doi.org\/10.1016\/j.ejca.2006.01.012","journal-title":"Eur J Cancer"},{"key":"1582_CR203","doi-asserted-by":"publisher","first-page":"7361","DOI":"10.1021\/jacs.2c13732","volume":"145","author":"LKB Tam","year":"2023","unstructured":"Tam LKB, Chu JCH, He L, Yang C, Han KC, Cheung PCK, Ng DKP, Lo PC (2023) Enzyme-responsive double-locked photodynamic molecular beacon for targeted photodynamic anticancer therapy. J Am Chem Soc 145:7361\u20137375. https:\/\/doi.org\/10.1021\/jacs.2c13732","journal-title":"J Am Chem Soc"},{"issue":"1","key":"1582_CR204","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-01319-4","volume":"8","author":"J Tan","year":"2017","unstructured":"Tan J, Cognetta A III, Diaz DB, Lum KM, Adachi S, Kundu S, Cravatt BF, Yudin AK (2017) Multicomponent mapping of boron chemotypes furnishes selective enzyme inhibitors. Nat Commun 8(1):1\u20138. https:\/\/doi.org\/10.1038\/s41467-017-01319-4","journal-title":"Nat Commun"},{"issue":"35","key":"1582_CR205","doi-asserted-by":"publisher","first-page":"25822","DOI":"10.1074\/jbc.m605142200","volume":"281","author":"M Tanaka","year":"2006","unstructured":"Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, Noji S, Yatomi Y, Aoki J, Arai H (2006) Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem 281(35):25822\u201325830. https:\/\/doi.org\/10.1074\/jbc.m605142200","journal-title":"J Biol Chem"},{"issue":"1","key":"1582_CR206","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1146\/annurev-pathol-011110-130303","volume":"6","author":"XH Tang","year":"2011","unstructured":"Tang XH, Gudas LJ (2011) Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol 6(1):345\u2013364. https:\/\/doi.org\/10.1146\/annurev-pathol-011110-130303","journal-title":"Annu Rev Pathol"},{"key":"1582_CR207","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.chembiol.2023.10.019","volume":"31","author":"Y Tao","year":"2024","unstructured":"Tao Y, Budhipramono A, Huang J, Fang M, Xie S, Kim J, Khivansara V, Dominski Z, Tong L, Drbander JKD, Nijhawan D (2024) Anticancer benzoxaborles block pre-mRNA processing by directly inhibiting CPSF3. Cell Chem Biol 31:139\u2013149. https:\/\/doi.org\/10.1016\/j.chembiol.2023.10.019","journal-title":"Cell Chem Biol"},{"issue":"1","key":"1582_CR208","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2015.04.008","volume":"96","author":"BA Teicher","year":"2015","unstructured":"Teicher BA, Tomaszewski JE (2015) Proteasome inhibitors. Biochem Pharmacol 96(1):1\u20139. https:\/\/doi.org\/10.1016\/j.bcp.2015.04.008","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"1582_CR209","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000473717","volume":"29","author":"SC Thorpe","year":"1996","unstructured":"Thorpe SC, Azmatullah S, Fellows GJ, Gingell JC, O\u2019Boyle PJ (1996) A prospective, randomised study to compare goserelin acetate (Zoladex\u00ae) versus cyproterone acetate (Cyprostat\u00ae) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol 29(1):47\u201354. https:\/\/doi.org\/10.1159\/000473717","journal-title":"Eur Urol"},{"issue":"7","key":"1582_CR210","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1039\/c0cs00154f","volume":"40","author":"S Touchet","year":"2011","unstructured":"Touchet S, Carreaux F, Carboni B, Bouillon A, Boucher JL (2011) Aminoboronic acids and esters: from synthetic challenges to the discovery of unique classes of enzyme inhibitors. Chem Soc Rev 40(7):3895\u20133914. https:\/\/doi.org\/10.1039\/c0cs00154f","journal-title":"Chem Soc Rev"},{"key":"1582_CR211","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejmech.2014.06.017","volume":"83","author":"V Troiano","year":"2014","unstructured":"Troiano V, Scarbaci K, Ettari R, Micale N, Cerchia C, Pinto A, Schirmeister T, Novellino E, Grasso S, Lavecchia A, Zappal\u00e0 M (2014) Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors. Eur J Med Chem 83:1\u201314. https:\/\/doi.org\/10.1016\/j.ejmech.2014.06.017","journal-title":"Eur J Med Chem"},{"issue":"4","key":"1582_CR212","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1248\/bpb.23.513","volume":"23","author":"M Tsuji","year":"2000","unstructured":"Tsuji M, Koiso Y, Takahashi H, Hashimoto Y, Endo Y (2000) Modulators of tumor necrosis factor.ALPHA. production bearing dicarba-closo-dodecaborane as a hydrophobic pharmacophore. Biol Pharm Bull 23(4):513\u2013516. https:\/\/doi.org\/10.1248\/bpb.23.513","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"1582_CR213","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1586\/era.10.203","volume":"11","author":"FM Uckun","year":"2011","unstructured":"Uckun FM, Pitt J, Qazi S (2011) JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia. Expert Rev Anticancer Ther 11(1):37\u201348. https:\/\/doi.org\/10.1586\/era.10.203","journal-title":"Expert Rev Anticancer Ther"},{"key":"1582_CR214","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jtemb.2017.10.008","volume":"45","author":"I Uluisik","year":"2018","unstructured":"Uluisik I, Karakaya HC, Koc A (2018) The importance of boron in biological systems. J Trace Elem Med Biol 45:156\u2013162. https:\/\/doi.org\/10.1016\/j.jtemb.2017.10.008","journal-title":"J Trace Elem Med Biol"},{"issue":"2","key":"1582_CR215","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.canlet.2008.04.050","volume":"267","author":"J Vandercappellen","year":"2008","unstructured":"Vandercappellen J, Van Damme J, Struyf S (2008) The role of CXC chemokines and their receptors in cancer. Cancer Lett 267(2):226\u2013244. https:\/\/doi.org\/10.1016\/j.canlet.2008.04.050","journal-title":"Cancer Lett"},{"issue":"2","key":"1582_CR216","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.canlet.2010.10.004","volume":"300","author":"ML Varney","year":"2011","unstructured":"Varney ML, Singh S, Li A, Mayer-Ezell R, Bond R, Singh RK (2011) Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases. Cancer Lett 300(2):180\u2013188. https:\/\/doi.org\/10.1016\/j.canlet.2010.10.004","journal-title":"Cancer Lett"},{"issue":"8","key":"1582_CR217","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1080\/10428194.2016.1263842","volume":"58","author":"DT Vogl","year":"2017","unstructured":"Vogl DT, Martin TG, Vij R, Hari P, Mikhael JR, Siegel D, Wu KL, Delforge M, Gasparetto C (2017) Phase I\/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. Leuk Lymphoma 58(8):1872\u20131879. https:\/\/doi.org\/10.1080\/10428194.2016.1263842","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"1582_CR218","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/ddr.20138","volume":"67","author":"TW von Geldern","year":"2006","unstructured":"von Geldern TW, Trevillyan JM (2006) The next big thing\u201d in diabetes: clinical progress on DPP\u2010IV inhibitors. Drug Dev Res 67(8):627\u2013642. https:\/\/doi.org\/10.1002\/ddr.20138","journal-title":"Drug Dev Res"},{"issue":"7","key":"1582_CR219","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00384-010-0939-0","volume":"25","author":"IA Voutsadakis","year":"2010","unstructured":"Voutsadakis IA, Patrikidou A, Tsapakidis K, Karagiannaki A, Hatzidaki E, Stathakis NE, Papandreou CN (2010) Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib. Int J Colorectal Dis 25(7):795\u2013804. https:\/\/doi.org\/10.1007\/s00384-010-0939-0","journal-title":"Int J Colorectal Dis"},{"issue":"20","key":"1582_CR220","first-page":"5749","volume":"62","author":"AE Wakeling","year":"2002","unstructured":"Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH (2002) ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62(20):5749\u20135754","journal-title":"Cancer Res"},{"issue":"2","key":"1582_CR221","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1593\/tlo.13133","volume":"6","author":"S Wang","year":"2013","unstructured":"Wang S, Wu Y, Hou Y, Guan X, Castelvetere MP, Oblak JJ, Banerjee S, Filtz TM, Sarkar FH, Chen X, Jena BP, Li C (2013) CXCR2 macromolecular complex in pancreatic cancer: a potential therapeutic target in tumor growth. Transl Oncol 6(2):216\u2013225. https:\/\/doi.org\/10.1593\/tlo.13133","journal-title":"Transl Oncol"},{"key":"1582_CR222","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115187","volume":"250","author":"X Wang","year":"2023","unstructured":"Wang X, Zhang W, Wen T, Miao H, Hu W, Liu H, Lei M, Zhu Y (2023) Design and discovery of novel dipeptide boronic acid ester proteasome inhibitors, an oral slowly-released prodrug for the treatment of multiple myeloma. Eur J Med Chem 250:115187. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115187","journal-title":"Eur J Med Chem"},{"issue":"8","key":"1582_CR223","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1016\/j.bmcl.2009.02.117","volume":"19","author":"T Watanabe","year":"2009","unstructured":"Watanabe T, Momose I, Abe M, Abe H, Sawa R, Umezawa Y, Ikeda D, Takahashi Y, Akamatsu Y (2009) Synthesis of boronic acid derivatives of tyropeptin: proteasome inhibitors. Bioorg Med Chem Lett 19(8):2343\u20132345. https:\/\/doi.org\/10.1016\/j.bmcl.2009.02.117","journal-title":"Bioorg Med Chem Lett"},{"issue":"19","key":"1582_CR224","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.1016\/j.bmcl.2010.07.122","volume":"20","author":"T Watanabe","year":"2010","unstructured":"Watanabe T, Abe H, Momose I, Takahashi Y, Ikeda D, Akamatsu Y (2010) Structure-activity relationship of boronic acid derivatives of tyropeptin: proteasome inhibitors. Bioorg Med Chem Lett 20(19):5839\u20135842. https:\/\/doi.org\/10.1016\/j.bmcl.2010.07.122","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"1582_CR225","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/00001813-200403000-00001","volume":"15","author":"CML West","year":"2004","unstructured":"West CML, Price P (2004) Combretastatin A4 phosphate. Anticancer Drugs 15(3):179\u2013187. https:\/\/doi.org\/10.1097\/00001813-200403000-00001","journal-title":"Anticancer Drugs"},{"key":"1582_CR226","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-015-0275-x","volume":"34","author":"D Westover","year":"2015","unstructured":"Westover D, Li F (2015) New trends for overcoming ABCG2\/BCRP-mediated resistance to cancer therapies. J Exp Clin Cancer Res 34:159. https:\/\/doi.org\/10.1186\/s13046-015-0275-x","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"1582_CR227","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tips.2006.02.004","volume":"27","author":"N White","year":"2006","unstructured":"White N, Burnstock G (2006) P2 receptors and cancer. Trends Pharmacol Sci 27(4):211\u2013217. https:\/\/doi.org\/10.1016\/j.tips.2006.02.004","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"1582_CR228","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bbrc.2009.05.022","volume":"385","author":"MS Won","year":"2009","unstructured":"Won MS, Im N, Park S, Boovanahalli SK, Jin Y, Jin X, Chung KS, Kang M, Lee K, Park SK, Kim HM, Kwon BM, Lee JJ, Lee K (2009) A novel benzimidazole analogue inhibits the hypoxia-inducible factor (HIF)-1 pathway. Biochem Biophys Res Commun 385(1):16\u201321. https:\/\/doi.org\/10.1016\/j.bbrc.2009.05.022","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"1582_CR229","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/17512433.2019.1570846","volume":"12","author":"J Yang","year":"2019","unstructured":"Yang J, Gong W (2019) Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer. Expert Rev Clin Pharmacol 12(3):173\u2013178. https:\/\/doi.org\/10.1080\/17512433.2019.1570846","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"1582_CR230","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/med.10043","volume":"23","author":"W Yang","year":"2003","unstructured":"Yang W, Gao X, Wang B (2003) Boronic acid compounds as potential pharmaceutical agents. Med Res Rev 23(3):346\u2013368. https:\/\/doi.org\/10.1002\/med.10043","journal-title":"Med Res Rev"},{"issue":"24","key":"1582_CR231","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1182\/blood-2017-10-813139","volume":"131","author":"M Ying","year":"2018","unstructured":"Ying M, Shao X, Jing H, Liu Y, Qi X, Cao J, Chen Y, Xiang S, Song H, Hu R, Wei G, Yang B, He Q (2018) Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2. Blood 131(24):2698\u20132711. https:\/\/doi.org\/10.1182\/blood-2017-10-813139","journal-title":"Blood"},{"issue":"28","key":"1582_CR232","doi-asserted-by":"publisher","first-page":"17174","DOI":"10.1016\/s0021-9258(17)44885-x","volume":"265","author":"M Yoshida","year":"1990","unstructured":"Yoshida M, Kijima M, Akita M, Beppu T (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265(28):17174\u201317179. https:\/\/doi.org\/10.1016\/s0021-9258(17)44885-x","journal-title":"J Biol Chem"},{"issue":"1","key":"1582_CR233","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1124\/mol.106.030163","volume":"71","author":"MT Young","year":"2007","unstructured":"Young MT, Pelegrin P, Surprenant A (2007) Amino acid residues in the P2X7 receptor that mediate differential sensitivity to ATP and BzATP. Mol Pharmacol 71(1):92\u2013100. https:\/\/doi.org\/10.1124\/mol.106.030163","journal-title":"Mol Pharmacol"},{"issue":"2","key":"1582_CR234","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/cmdc.200900448","volume":"5","author":"H Zettl","year":"2010","unstructured":"Zettl H, Schubert-Zsilavecz M, Steinhilber D (2010) Medicinal chemistry of incretin mimetics and DPP-4 inhibitors. ChemMedChem 5(2):179\u2013185. https:\/\/doi.org\/10.1002\/cmdc.200900448","journal-title":"ChemMedChem"},{"issue":"14","key":"1582_CR235","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1016\/j.bmcl.2018.06.004","volume":"28","author":"W Zhang","year":"2018","unstructured":"Zhang W, Bai H, Han L, Zhang H, Xu B, Cui J, Wang X, Ge Z, Li R (2018) Synthesis and biological evaluation of curcumin derivatives modified with \u03b1-amino boronic acid as proteasome inhibitors. Bioorg Med Chem Lett 28(14):2459\u20132464. https:\/\/doi.org\/10.1016\/j.bmcl.2018.06.004","journal-title":"Bioorg Med Chem Lett"},{"issue":"14","key":"1582_CR236","doi-asserted-by":"publisher","first-page":"6765","DOI":"10.1021\/acs.jmedchem.9b00736","volume":"62","author":"J Zhang","year":"2019","unstructured":"Zhang J, Zhang J, Hao G, Xin W, Yang F, Zhu M, Zhou H (2019) Design, synthesis, and structure-activity relationship of 7-propanamide benzoxaboroles as potent anticancer agents. J Med Chem 62(14):6765\u20136784. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00736","journal-title":"J Med Chem"},{"key":"1582_CR237","doi-asserted-by":"publisher","first-page":"37435","DOI":"10.1021\/acsami.5c02939","volume":"17","author":"N Zhang","year":"2025","unstructured":"Zhang N, Li R, Shen H, Li H, Liu S, Liao H, Cong W, Hu X, Hu H (2025) Self-assembled molecular glue prodrug system for enhanced synergistic tumor therapy by combining CDK12 protein degradation and immunotherapy. ACS Appl Mater Interfaces 17:37435\u201337447. https:\/\/doi.org\/10.1021\/acsami.5c02939","journal-title":"ACS Appl Mater Interfaces"},{"issue":"5","key":"1582_CR238","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/cmdc.201700047","volume":"12","author":"P Zhao","year":"2017","unstructured":"Zhao P, Nettleton DO, Karki RG, Z\u00e9cri FJ, Liu SY (2017) Medicinal chemistry profiling of monocyclic 1,2-azaborines. ChemMedChem 12(5):358\u2013361. https:\/\/doi.org\/10.1002\/cmdc.201700047","journal-title":"ChemMedChem"},{"key":"1582_CR239","doi-asserted-by":"crossref","unstructured":"Zhi L, Martinborough E (2001) Chapter 17. ED, Annette M. Doherty. Selective androgen receptor modulators (SARMs). In: Annual reports in medicinal chemistry. Elsevier, pp 169\u2013180","DOI":"10.1016\/S0065-7743(01)36057-8"},{"issue":"2","key":"1582_CR240","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3144","volume":"14","author":"C Zhou","year":"2012","unstructured":"Zhou C, Zhong Q, Rhodes LV, Townley I, Bratton MR, Zhang Q, Martin EC, Elliott S, Collins-Burow BM, Burow ME, Wang G (2012) Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res 14(2):R45. https:\/\/doi.org\/10.1186\/bcr3144","journal-title":"Breast Cancer Res"},{"issue":"5","key":"1582_CR241","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.bmc.2005.10.003","volume":"14","author":"YQ Zhu","year":"2006","unstructured":"Zhu YQ, Pei JF, Liu ZM, Lai LH, Cui JR, Li RT (2006) 3D-QSAR studies on tripeptide aldehyde inhibitors of proteasome using CoMFA and CoMSIA methods. Bioorg Med Chem 14(5):1483\u20131496. https:\/\/doi.org\/10.1016\/j.bmc.2005.10.003","journal-title":"Bioorg Med Chem"},{"issue":"19","key":"1582_CR242","doi-asserted-by":"publisher","first-page":"6851","DOI":"10.1016\/j.bmc.2009.08.023","volume":"17","author":"Y Zhu","year":"2009","unstructured":"Zhu Y, Yao S, Xu B, Ge Z, Cui J, Cheng T, Li R (2009a) Design, synthesis and biological evaluation of tripeptide boronic acid proteasome inhibitors. Bioorg Med Chem 17(19):6851\u20136861. https:\/\/doi.org\/10.1016\/j.bmc.2009.08.023","journal-title":"Bioorg Med Chem"},{"issue":"14","key":"1582_CR243","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1021\/jm9005093","volume":"52","author":"Y Zhu","year":"2009","unstructured":"Zhu Y, Zhao X, Zhu X, Wu G, Li Y, Ma Y, Yuan Y, Yang J, Hu Y, Ai L, Gao Q (2009b) Design, synthesis, biological evaluation, and structure\u2212activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, part I: comprehensive understanding of the SAR of \u03b1-amino acid boronates. J Med Chem 52(14):4192\u20134199. https:\/\/doi.org\/10.1021\/jm9005093","journal-title":"J Med Chem"},{"issue":"24","key":"1582_CR245","doi-asserted-by":"publisher","first-page":"8619","DOI":"10.1021\/jm1009742","volume":"53","author":"Y Zhu","year":"2010","unstructured":"Zhu Y, Wu G, Zhu X, Ma Y, Zhao X, Li Y, Yuan Y, Yang J, Yu S, Shao F, Lei M (2010a) Synthesis, in vitro and in vivo biological evaluation, and comprehensive understanding of structure\u2212activity relationships of dipeptidyl boronic acid proteasome inhibitors constructed from \u03b2-amino acids. J Med Chem 53(24):8619\u20138626. https:\/\/doi.org\/10.1021\/jm1009742","journal-title":"J Med Chem"},{"issue":"5","key":"1582_CR246","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1021\/jm901407s","volume":"53","author":"Y Zhu","year":"2010","unstructured":"Zhu Y, Zhu X, Wu G, Ma Y, Li Y, Zhao X, Yuan Y, Yang J, Yu S, Shao F, Li R, Ke Y, Lu A, Liu Z, Zhang L (2010b) Synthesis, in vitro and in vivo biological evaluation, docking studies, and structure\u2212activity relationship (SAR) discussion of dipeptidyl boronic acid proteasome inhibitors composed of \u03b2-amino acids. J Med Chem 53(5):1990\u20131999. https:\/\/doi.org\/10.1021\/jm901407s","journal-title":"J Med Chem"},{"issue":"1","key":"1582_CR247","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/cbic.201200571","volume":"14","author":"TJ Zimmermann","year":"2013","unstructured":"Zimmermann TJ, B\u00fcrger M, Tashiro E, Kondoh Y, Martinez NE, G\u00f6rmer K, Rosin-Steiner S, Shimizu T, Ozaki S, Mikoshiba K, Watanabe N, Hall D, Vetter IR, Osada H, Hedberg C, Waldmann H (2013) Boron-based inhibitors of acyl protein thioesterases 1 and 2. ChemBioChem 14(1):115\u2013122. https:\/\/doi.org\/10.1002\/cbic.201200571","journal-title":"ChemBioChem"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-025-01582-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12272-025-01582-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-025-01582-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:35:42Z","timestamp":1764952542000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12272-025-01582-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":245,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1582"],"URL":"https:\/\/doi.org\/10.1007\/s12272-025-01582-w","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}